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Lantibiotics like mutacin 1140 are receiving a considerable amount of attention
because of their broad spectrum of activity, high potency, low immunogenicity, and good
structural stability. Mutacin 1140 is produced by Streptococcus mutans JH1140 and is a
type A (I) lantibiotic. Lantibiotics are ribosomally synthesized bacteriocins that undergo
post-translational modifications to form lanthionine or β-methyllanthionine rings as well
as 2, 3-didehydroalanine (Dha), 2, 3-didehydrobutyrine (Dhb), and S-amino vinyl-Dcysteine (AviCys). Their mode of action is pore formation and/or abduction of lipid II
from the site of new cell wall synthesis.
In order to gain further knowledge of both the structural integrity and structurefunction relationship of type A (I) lantibiotics, chemical modifications or site directed
mutagenesis was utilized. In the first aim of this study, two type A (I) lantibiotics were
used, nisin A produced by Lactococcus lactis and gallidermin produced by
Staphylococcus gallinarium. They both share homology in rings A and B, the lipid II
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binding domain, with rings A and B of mutacin 1140. What was discovered was that
oxidation of the lanthionine rings results in the complete loss of bioactivity due to the
loss of affinity for lipid II. Interestingly, the lateral assembly ability of the oxidized
variants is not affected.
In the second aim, the dehydrated threonine residue (Dhb) at position 14 in
gallidermin underwent chemical modification using several thiol-compounds. The results
showed that this residue is amendable to modification through thiol chemistry with some
loss of bioactivity. However, the MICs for the chemical variants were still in the
nanomolar range. From this work the first ever in vivo images of gallidermin were
produced.
The last aim of the study utilized site directed mutagenesis of the mutA gene of
mutacin 1140 to determine the role of various residues in ring A and the hinge region of
the peptide. It was determined that neither Trp4, Dha5, nor Arg13 are important for
bioactivity but a set distance between rings A and B is essential. The majority of the
mutants constructed showed either similar or increased bioactivity.
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CHAPTER I
A REVIEW OF TYPE A LANTIBIOTICS

Abstract
Lantibiotics are ribosomally synthesized bacteriocins produced by various grampositive bacteria. They undergo several post-translational modifications to yield unusual
amino acids and structures such as lanthionine, methyllanthionine, 2,3-didehydroalanine,
and 2,3-didehydrobutyrine. They are divided into groups and sub-groups based on size,
charge, structure, enzymatic requirements, and leader sequence homology. The
emergence of multi-drug resistant pathogens have led to an increased interest in
lantibiotics, as they are active against various multi-drug resistant pathogens and have
low cytotoxicity. Lipid II is used as a docking molecule for pore formation or it can be
sequestered into a complex making it unavailable for use in new cell wall synthesis.
The applications for lantibiotics are numerous. Nisin, a well-known lantibiotic
produced by Lactococcus lactis, has been safely used in the food and dairy industry for
over 50 years. Other lantibiotics such as gallidermin (Staphylococcus gallinarium), has
been found to be useful in the treatment of bovine mastitis while mutacin 1140
(Streptococcus mutans JH1140), was determined to be useful in the prevention of dental
caries in canines. The combination of spectrum of activity and application potential of
lantibiotics led to extensive research efforts. Some of this research was mutagenesis
1

studies. In these studies most of the variants generated showed decreased bioactivity
when compared to the wild-type. Very few mutants were generated that had enhanced
bioactivity.

Introduction
Bacteriocins are proteinaceous molecules produced by bacteria to inhibit the
growth of competing, closely related bacterial strains. Although several classes of
bacteriocins exist, most can be grouped into either class I or II. Class I and II bacteriocins
are ribosomally synthesized peptides that are produced by various gram-positive bacteria
and differ in the presence or absence of modified amino acids. Class I bacteriocins have
modified amino acids (lantibiotics) while class II do not (non-lantibiotics). The
similarities that they share are in size (<5kDa for class I and <10kDa for class II), charge
(mostly cationic), and structural components, such as hydrophobicity or amphiphilicity
(1, 2). These two classes are the most studied due to their abundance, possible industrial
applications, and therapeutic potentials.
The work in this dissertation is focused on the bacteriocin mutacin 1140 and other
related antibiotics. Mutacin 1140 is a type A (class I) lantibiotic produced by
Streptococcus mutans. Lantibiotics are class I bacteriocins that undergo post-translational
modifications that lead to the formation of various unusual amino acids such as
lanthionine and/or β-methyllanthionine as well as others (see Biosynthesis of Lantibiotics
section for further details). They are divided into three groups: type A, B, and twocomponent. Type A lantibiotics have a molecular mass greater than 2100 Da, a net
2

positive charge ranging from 2-7, and a rigid ring conformation separated by areas of
flexibility. The primary bactericidal activity for this group was once believed to be pore
forming, but recently it has been discovered that abduction of lipid II from the site of new
cell wall synthesis may be the primary activity with pore forming activity being
secondary (3-5). Type A lantibiotics are subdivided into A (I) and A (II) based on size,
charge, and leader peptide sequence (Table 1.1). Type B lantibiotics are typically less
than 2100 Da, have a net charge that is either neutral or slightly anionic, and have a
compact globular shape. Their bactericidal activity is primarily associated with the
inhibition of essential enzymes. The two-component lantibiotics are characterized by
having two peptides encoded on adjacent genes that work together to exhibit their
bactericidal activity. The α-peptide is structurally similar to type B lantibiotics while the
β-peptide resembles an elongated type A lantibiotic. Separately they are either inactive or
only slightly active. Together, their mechanism of action is thought to be the same as
mutacin 1140 (1, 6).

3

4
2986
3442
3317
4635

Bacillus subtilis
Bacillus subtilis
Bacillus subtilis
Carnobacterium
piscicola

Ericin S

Subtilin

Carnocin UI49

2424

3029

3353
3330
3327
3457

Mol.
Weight

Ericin A

Streptin

Streptococcus
uberis
Streptococcus
pyogenes

Lactococcus
lactis

Nisin A
Nisin Z
Nisin Q
Nisin F

Nisin U

Producer Strain

Lantibiotic

n.d.

+1
E
2-K
+2
E
3-K

+3
K
+3
D
2-K
+2
K

+3
K

Net
Charge

1

1

1

2

1

1

n.d.

A (I)

Lan

n.d.

4

4

4

1

4

4

n.d.

2

2

1

0

2

2

n.d.

1

1

0

3

1

1

Post Translational Modifications
MeLan
Dha
Dhb

Type A Lantibiotics Characterized as of May 2011

Table 1.1

n.d.

0

0

0

0

0

0

Other

(16, 17)

(15)

(14)

(14)

(13)

(12)

(7)
(8)
(9)
(10, 11)

Ref

5
2246
2230
2107
3488

3133

3032

Bacillus claussi
Staphylococcus
epidermidis
Staphylococcus
epidermidis
Staphylococcus
epidermidis

Clausin

Pep 5

Epicidin 280

Epilancin K7

2364

2263
2270
2266

Microbiospora
sp.

Streptococcus
mutans

Mol.
Weight
2164
2151
2164
2166
2164

Microbisporicin A1
A2

Mutacin I

Mutacin 1140
Mutacin B-Ny266
Mutacin III

Gallidermin

Staphylococcus
epidermidis

Epidermin
[Val1-Leu6]-epidermin
Staphylococcin 1580
Staphylococcin T
S. cohnii T strain
Staphylococcus
gallinarium

Producer Strain

Lantibiotic

+7
Oxob
2-R
6-K
+4
D/Hop
2-R
4-K
+5
Hop
6-K

0

0

+3
K
R
NH2

+3
2-K
NH2
+3
2-K
NH2

Net
Charge

1

1

2

3

4

3

2

2

2

Lan

Table 1.1 continued

2

2

1

1

1

0

1

1

1

2

0

0

1

1

2

1

0

0

2

1

2

2

1

0

1

1

1

AviCys

AviCys

AviCys

Other

Oxo/
hydroxypropion
yl
Hydroxypropio
nyl

Oxobutyryl

5-chloro-Trp &
3, 4-diOHPro
4OHPro/AviCys
AviCys

Post Translational Modifications
MeLan
Dha
Dhb

(31)

(30)

(29)

(28)

(27)

(26)

(23)
(24)
(25)

(22)

(18)
(19)
(20)
(21)

Ref

6

Salivaricin B

Salivaricin
A2
A3
A4
A5

Salivaricin A1

Salivaricin A

2364
2312
2340
2328
2740

Streptococcus
salivarius k12

2321

2315

Streptococcus
salivarius
Streptococcus
pyogenes
Streptococcus
salivarius
k12
JH
9
H21F

2795

2901
3000
3245
2734
3244

Lactococcus
lactis
Streptococcus
mutans

Lacticin 481
Lacticin J46
Mutacin II
Mutacin K8
Mutacin H29B
Streptococcus
pyogenes

3173

Staphylococcus
epidermidis

Epilancin 15X

Streptococcin AFF-22

Mol.
Weight

Producer Strain

Lantibiotic

0

0

0

0

+1
E
2-R
+1
E
2-K

0

Net
Charge
+6
Hop
R
6-K
A (II)

3

1

1

1

0

2

2

2

2

1

2
1

1
0

2

2

0

0

0

0

0

0
0

1

2

0

0

0

1

1

1
1

3

Other

0

0

0

0

0

0

0
0

hydroxypropion
yl

Post Translational Modifications
MeLan
Dha
Dhb

2
2

1

Lan

Table 1.1 continued

(43)

(42)

(41, 42)

(40)

(39)

(33)
(34)
(35, 36)
(37)
(38)

(32)

Ref

Streptococcus
bovis HJ50

Bovicin HJ50

2960

2675
3877

2983

Staphylococcus
warneri
Ruminococcus
gnavus
Bacillus subtilis

Paenibacillus
polymyxa

Ruminicoccin A

Sublancin 168

Paenibacillin

2658
2795

3428

2860
2910

Mol.
Weight

Nukacin ISK-1

Macedocin

Micrococcus
varians
Streptococcus
mecedonicus

Butyrivibrio
fibriosolvens

Butyrivibriocin
OR79A/OR79B

Variacin

Producer Strain

Lantibiotic

1

2

n.d.

2

0

1

Lan

1

1

n.d.

1

2

2

2

0

0

0

n.d.

0

0

0

2

0

2

1

n.d.

1

2

1

2 disuphide
bridges

0

0

n.d.

0

disulphide
bridge

0

Other

N-acetylated
Ala

Post Translational Modifications
MeLan
Dha
Dhb

+3
2-R
0
1
K
Peptide Not Yet Assigned
+4
actl-A
2
3
5-K

0

0
+2
D
3-K

+2
2-D
R
3-K
-1
E

0

Net
Charge

Table 1.1 continued

(53, 54)

(52)

(51)

(50)

(48, 49)

(47)

(45, 46)

(44)

Ref

Each subgroup is headed by the representative structure. Lan: lanthionine, MeLan: methyllanthionine, Dha: 2,3-didehydroalanine,
Dhb: 2,3-didehydrobutyrine, AviCys: aminovinyl-D-cysteine, acytl-A: N-acetylated alanine, Hop: hydroxypropionyl, Oxob:
Oxobutyryl, and n.d: not determined. Note-single letter codes are used for the amino acids responsible for net charge. Bold print
indicates predicted mass.
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Biosynthesis of Lantibiotics
Lantibiotics are produced as a prepropeptide that undergoes extensive posttranslational modifications. These modifications result in the formation of the hallmark
residues lanthionine (Lan) and/or β-methyllanthionine (MeLan) from which the group is
named. Other unusual amino acids found in type A lantibiotics are: 2, 3-didehydroalanine
(Dha), 2, 3-didehydrobutyrine (Dhb), S-amino vinyl-D-cysteine (AviCys), 2oxopropionyl, 2-oxobutyryl, and hydroxypropionyl residues (Figure 1.1) (3). Other less
encountered modified residues are D-alanine, lysinoalanine, S-amino-D-methylcysteine,
and 2-hydroxy-aspartate (1). The structural genes for lantibiotics are encoded in a
biosynthetic gene cluster that contains all the necessary genes needed for modification,
export, and cleavage, as well as those responsible for regulation and self-immunity. The
proprepeptide is encoded by the lanA gene and contains a long N-terminal leader
sequence consisting of 23-59 amino acid residues and a C-terminal structural region
(propeptide). The post-translational modifications that lead to the formation of thioether
rings are performed by either LanB/LanC for type A (I) lantibiotics or LanM for type A
(II) lantibiotics (1, 6).

8

Figure 1.1
Modified Residues Commonly Found in Type A Lantibiotics
Chemical structures of modified residues commonly found in type A (I) lantibiotics.
Structures were produced using ACD/ChemSketch.

LanB (dehydratase) performs the dehydration of serine and threonine residues to
yield the α, β-unsaturated amino acids, Dha and Dhb respectively. This step is crucial as it
creates an electrophilic dehydro amino acid needed for the cyclization of a nucleophilic
thiolate (cysteine) to form the thioether bridge (55, 56). It has been shown that deletion or
disruption of spaB and eriB in the producing microorganism leads to the prevention of
subtilin and ericin A/S production respectively signifying its importance (14, 57).
9

Cyclization of dehydro amino acids to the sulfhydryl group of cysteine is
performed by LanC (cyclase). This is an intramolecular Michael addition that occurs
spontaneously and results in the formation of a thioether bridged di-carboxy-di-amino
acid (1, 55). Since this reaction occurs spontaneously, LanC is thought to act more to
regulate the regio- and stereochemistry of the lanthionine/methyllanthionine bridges (1).
The importance of the LanC gene is demonstrated in a study where pepC is deleted in
Staphylococcus epidermidis. The result was an incorrectly modified pep5 fragment that
contains only one of three lanthionine residues (58).
As previously mentioned, type A (I) lantibiotics use LanB/C to form the
lanthionine rings while type A (II) lantibiotics use LanM. The absence of any other
enzymes that can catalyze the dehydration and cyclization reactions in the type A (II)
gene cluster suggesst that LanM performs the job of both LanB and C. Evidence of the
importance of LanM is demonstrated in studies in which the deletion or inactivation of
mutM and lasM in the producing microorganism resulted in the elimination of the
production of mutacin II and lactocin S respectively (59, 60).
For lantibiotics that belong to the epidermin group (gallidermin, mutacin 1140,
etc.), LanD (oxidoreductase and flavoprotein) is used to catalyze the oxidative
decarboxylation of the C-terminal cysteine to yield S-aminovinyl-D- cysteine (AviCys) or
S-amino-D-methyl-cysteine (61, 62). In order for the enzyme to be active, the C-terminal
cysteine must have a free thiol and carboxylate. The final three amino acids must also
have a general sequence consensus of [V/I/L/F/W/Y/(M)]-[A/S/V/T/C/(I/L)]-C (1, 63).
Previously it was mentioned that lantibiotics exist as a prepropeptide that contain
an N-terminal leader sequence and C-terminal propeptide. For some lantibiotics after
10

modification of the propeptide, the entire protein is transported to the extracellular
medium by the ATP-dependent transporter LanT (1, 61). Its role as a transporter was
made evident in an experiment performed by Qiao et. al. where the nisT gene was deleted
in Lactococcus lactis resulting in the build-up of cytoplasmic processed nisin (64). Once
in the extracellular medium, the leader sequence is cleaved at a conserved cleavage site
by LanP (serine protease) yielding the mature active peptide (Figure 1.2) (1, 61).

Figure 1.2
Schematic of Lantibiotic Biosynthesis.
Biosynthesis begins with the transcription of the prepropetide by LanA. LanB then
catalyzes the dehydration of serine and threonine to yield Dha and Dhb after which LanC
forms the lanthionine or methyllanthionine bridges. The processed prepropeptide is then
transported to the extracellular medium by the ATP-transporter LanT where the leader
sequence is cleaved by LanP producing the active mature lantibiotic.

Other modifications that can occur in lantibiotics such as pep5 and lactocin S
include the spontaneous deamination of N-terminally exposed Dha or Dhb to yield 2oxopropionyl and 2-oxobutyryl residues, respectively (31, 65). The 2-hydroxypropionyl
residuefound in epicidin K7 and 280 is formed from the reduction of the 2-oxopropionyl
11

residue (31, 65). A newly discovered gene belonging to the oxidoreductase family
designated eciO was found in the gene cluster of epicidin 280 and is thought to catalyze
the reduction of 2-oxopropionyl to 2-hydroxypropionyl(30).
The Lan gene cluster for mutacin 1140 is still unresolved. Only 2086bp have been
sequenced for mutacin 1140's producer strain Streptococcus mutans (Accession #
AF051560).The four open reading frames that have been identified consist of orfX and
orfY which have no known homology and unknown functions, LanA (mutacin 1140
prepropeptide), and a portion of LanB (dehydrotase) (66).
The location of the enzymes responsible for the post-translational modifications
was discovered through experiments that showed that LanB, C, and T form a membrane
associated complex. The experiments performed were western blot analysis of vesicle
preparations, yeast two-hybrid analysis, and coimmunoprecipitation experiments (67, 68).
To further confirm that these enzymes exist as a membrane bound lanthionine synthetase
complex, purified epidermal LanB and C enzymes were added to unmodified epidermin
with no post-translational modifications occurring (69). From this data, the researchers
concluded that the enzymatic activity of LanB and C occurs only when the complex is
formed. However, recent studies using NisB, C, and T show that both NisB and C are
active independent of each other (70).
Regulation of lantibiotic production is performed mostly through a twocomponent system via quorum sensing. In this system an autoinducer/pheromone
(secreted by the bacteria through the ATP-binding cassette or present in the environment)
binds to a membrane bound histidine kinase causing the phosphorylation of a sensor
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protein that in turns transfers the phosphate to a cytoplasmic regulator protein that
modulates the expression of various genes (71). This is used by most lantibiotics.
Nisin acts as its own autoinducer setting off a cascade of reactions that result in
the transfer of a phosphate group from NisK to the aspartate on NisR. The activated NisR
in turns binds to the nisA and nisF operons activating the transcription of both
nisABTCIP (biosynthesis) and nisFEG (immunity) (72). Subtilin production is regulated
similar to nisin, however, subtilin has a second system that utilizes sigma factor H (ơH)
which is an endogenous transcriptional regulator that is controlled by cell density (73).
Mutacin II production requires MutR (a regulatory protein homologous to the family of
Rgg transcription regulators) and unknown media components to activate the mutA and
mutR genes leading to transcription of mutAMTFEG (74). Mutacin II production is
different from the system used by nisin as it has no histidine kinase. The lacticin 481 gene
cluster has no known regulatory proteins. Investigations were conducted for lacticin 481
and it was discovered that it utilizes pH control of P1 and P3 promoters upstream of lctA
to regulate its production (75).
Lantibiotics are active against species that are closely related to their producer.
Therefore a mechanism is needed that will protect the producer from its product. This
system for lantibiotics is composed of either a single immunity protein termed LanI
and/or an ABC transporter that consists of two to three subunits (LanFE(G)) which can
act alone or in connection with an ancillary protein termed LanH (76).
Subtilin, a lantibiotic closely related to nisin, requires the presence of SpaI and
SpaFEG for complete immunity. SpaI is believed to sequester subtilin at the cytoplasmic
membrane preventing it from forming pores, and SpaFEG is believed to function by
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pumping subtilin from the cell into the extracellular medium (77). Nukacin ISK-1 uses
NukH (an accessory protein that binds to nukacin ISK-1and neutralizes it) and NukFEG
to confer immunity (78). Lantibiotics such as pep5 and epidermin utilize only a single
component of the immunity system, PepI and EpiFEG respectively (79, 80).
In summary, biosynthesis of lantibiotics begins with the transcription of the
prepropetide by LanA. LanB then catalyzes the dehydration of serine and threonine to
yield Dha and Dhb. Subsequently, LanC forms the lanthionine or methyllanthionine
bridges. For the members of the epidermin group, LanD catalyzes the decarboxylation of
the C-terminal cysteine to yield AviCys. The processed prepropeptide is then transported
to the extracellular medium (LanT) where the leader sequence is cleaved (LanP)
producing the active mature lantibiotic (Figure 1.2).

Covalent Structure of Type A Lantibiotics
Lantibiotics are a group of antimicrobial peptides whose structures are both
complex and interesting. The sub-type group the peptide is assigned depends on the
structure. The general structure of type A, B, and two-component lantibiotics were
discussed previously. Type A lantibiotics are characterized as being elongated with rigid
ring structures separated by areas of flexibility. In comparison to type A lantibiotics, type
B have a more globular shape. The two-component lantibiotics seem to structurally
embody both types as the α-peptide is structurally similar to the type B group while the βpeptide resembles type A lantibiotics (Figure 1.3). Type A lantibiotics are broken down
into two groups A (I) and A (II) based on the enzyme(s) used in their modifications. They
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are further broken down into four subgroups based on sequence homology to the
representative structure. These subgroups are: nisin A, epidermin, pep5, and lacticin 481.
Structural representatives from these groups are found in Figure 1.4.

Figure 1.3
Comparisons of the Covalent Structure of Type A, B, and Two-Component Lantibiotics
Dhb: didehydrobutyrine, Ala-S-Ala: lanthionine, Abu-S-Ala: methyllanthionine, Ala-Lys:
lysinoalanine
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Figure 1.4
Covalent Structure of Several Type A Lantibiotics
Dhb: didehydrobutyrine, Dha: didehydroalanine, Ala-S-Ala: lanthionine, Abu-S-Ala:
methyllanthionine, Cys-S-S-Cys: disulphide bridge

The nisin subgroup consists of nisin A, its natural variants (Z, Q, F, and U),
streptin, ericin A and S, subtilin, and a newly discovered lantibiotic named carnocin UI49
(Table 1.1). The A/B rings, which are thought to be the lipid II binding motif, are
conserved for this subgroup. Nisin F, Q and Z differ from nisin A at position 27 where
they contain an asparagine instead of a histidine. The only other difference between nisin
A and nisin F is a valine at position 30 which is also present in nisin Q. Nisin Q also has a
Val15 and Leu21 instead of Ala15 and Met21 (7-9, 11) (Table 1.2). Out of all of the
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variants discovered of nisin A, nisin U has the most differences. This variant is 3 amino
acids shorter than nisin A and has 8 different amino acids in its structure (12). Subtilin
has a similar thioether bridging pattern to nisin A and shares a 61% homology to nisin Z
(15). Ericin S and subtilin differ by only four amino acids and they share similar
lanthionine-bridge patterns (Table 1.2). Although ericin A differs from subtilin by sixteen
amino acids and two C-terminal bridging patterns, it shares a 75% homology to ericin S
(14). Streptin has only 23 amino acids as compared to 34 for nisin A, and it differs from
nisin A and subtilin in that it has a serine between the glycine and cysteine residues in the
conserved LCTPGC propeptide motif (13) (Table 1.2). The newly discovered lantibiotic
carnocin UI49 has been shown to have activity similar to nisin, but its complete structure
has not been fully characterized (17, 81).
The epidermin subgroup comprises of epidermin, [Val1-Leu6]-epidermin,
staphylococcin 1580 (T), gallidermin, mutacin 1140, mutacin B-Ny266, mutacin III,
mutacin I, and new members microbisporicin A1/A2, and clausin (Table 1.1). All of the
members of this group have a C-terminal cysteine that gets decarboxylated to yield
AviCys. The majority of this group are natural variants of epidermin with one differing at
positions one and six as with [Val1-Leu6]-epidermin and position six (Leu instead of Ile)
as with gallidermin (18, 19, 22) (Table 1.2). Through amino acid sequencing it was
discovered that staphylococcin 1580 and T are identical to epidermin and gallidermin
respectively (20, 21). Mutacin 1140 and mutacin III have identical structures and differ
from mutacin B-Ny266 by only two amino acids (Table 1.2). They share a 77% identity
to epidermin and 62.5% identity with mutacin I (1, 23, 24, 26). Clausin, a new member of
the epidermin group, has a 75% sequence identity to mutacin 1140 and retains the
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classical motif of the A/B lanthionine rings which is common for the type A (I)
lantibiotics (28) (Table 1.2). The second newest member of the group, microbisporicin
A1/A2, has identical ring A, B, D, and E topology as epidermin and is the most potent
antibacterial among the known lantibiotics. It is also the only lantibiotic that has the
unsual post-translational modifications that yield 5-chloro-tryptophan and mono- (A2) or
bis-hydroxylated proline (A1) (27).
The last subgroup of type A (I) lantibiotics is the pep5 group and it consists of
pep5, epicidin 280, epilancin K7, and epilancin 15X (Table 1.1). Members of this group
are strongly cationic and contain three thioether rings. Members of this group also are
characterized as having an N-terminal amino acid that is converted to oxo-propionyl or
butyrl residue by spontaneous deamination of Dha or Dhb, and in some cases is reduced
tohydroxypropionyl (29-32). Epilancin K7 and 15X have a 68% sequence identity,
identical lanthionine rings, and the same N-terminal amino acid (hydroxypropionyl) (32).
Epicidin 280 and pep5 share a 75% amino acid sequence identity and has the same Nterminal amino acid as epilancin K7 and 15X (1, 30) (Table 1.2).
The type A (II) lacticin 481 group is the largest subgroup of all the lantibiotics. Its
members consist of lacticin 481 and J46; mutacin II, K8, and H29B; streptococcin AFF22; salavariacin A, A1-A5, and B; butyrivibriocin OR79A/B; bovicin HJ50; variacin;
macedocin; nukacin ISK-1; ruminicoccin A; and sublancin 168 (Table 1.1). Members of
this group are characterized as having a slight to no net charge at neutral pH and an
unbridged N-terminus with a globular C-terminus (71). They also have conserved leader
peptide residues, 18 of 21 at their C-terminal. The conserved motif is
[EVSxxELxxIxGG] with the amino acids at positions -2 and -1 being either a double
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glycine or glycine-alanine (71). The propeptide generally has 22 conserved residues with
6 invariants and a double cysteine or CCS C-terminus (71). Assignment to this group is
based on homology to the leader/propeptide sequence of lacticin 481 and/or similarity of
the bridging patterns. There are eight main members of this group, lacticin 481, mutacin
II, streptococcin A-FF22, salivariacin A, butyrivibriocin OR79A, variacin, nukacin ISK1, and ruminicoccin A and all other members of the group are variants of the above with
the exception of bovicin and sublancin 168 (71). Bovicin HJ50 differs from the other
members of the group in that it has a TVS motif instead of the conserved EVS motif of
the leader peptide. Its propeptide also differs in that it has 4 cysteines instead of the usual
3 cysteines found for the other group members (46). Sublancin 168 is the only member
of the group with 2 disulphide bridges, bovicin has only one, (Figure 1.4) thus its
assignment to the group is based on the leader peptide motif instead of structure (46, 52).
Although variacin has a 92% structural identity to lacticin 481, it is the only member of
the group that is negatively charged due to a glutamic acid residue (Table 1.1) (47).
Paenibacillin is a unique lantibiotic. It is considered one of the most post-translationally
modified due to the presence of an unusual N-terminal acetylated alanine and number of
modified residues (54). Group assignment for paenibacillin has not yet been determined.
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Table 1.2
Sequence Alignment of Several Type A Lantibiotics
Nisin A
Nisin Q
Subtilin
Ericin S

ITSISLCTPGCKTGALMGCNMKTATCHCSIVHSK
ITSISLCTPGCKTGVLMGCNLKTATCNCSVVHSK
WKSESLCTPGCVTGALQTCFLQTLTCNCKI--SK
WKSESVCTPGCVTGVLQTCFLQTITCNC--HISK

Epidermin
Gallidermin
Mutacin 1140
Clausin

IASKFICTPGCAKTGSFNSYCC
IASKFLCTPGCAKTGSFNSYCC
FKSWSLCTPGCARTGSFNSYCC
FTAVSPATPGAGETGAFNAPA

Pep5
Epicidin 280
Epilancin K7

TAGPA---IRASVKQCQKT-LKATRLFTVSCKGK-NGCK
SLGPA---IKATRQVCP----KATRFVTVSCK-K-SDC
SASVLKTSIKVSKKYC-----KGV---TLTC----GCNITGGK

Lacticin 481
Mutacin II
Salivariacin A
Variacin
Sublancin 168

KGGSGVIHTISHECNMNSWQFVFTCCS
NRWWQGVVPTVSYECRMNSWNHVFTCC
AKRGSGWIATITDDCP-NS---VFVCC
GGSGVIPTISHECHMNSFQFVFTCCS
GLGKAQCAALWLQCASGGTIGCGGGAVACQNYRQFCR

Each sub-group’s representative peptide is in bold print. Residues involved in thioether
linkages or disulphide bridges like those found in sublancin 168 are highlighted green.
Dehydrated residues that result in the formation of didehydroalanine or
didehydrobutyrine are highlighted in red. Residues that undergo decarboxylation or
deamination are highlighted blue.

Bactericidal Function of Type A Lantibiotics
Lantibiotics tend to be active against species closely related to their producer
strain or found within their ecological niche. These are mainly gram-positive bacteria
some of which are important nosocomal pathogens like methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant S. aureus (VRSA). Variacin
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has been found to be active against various species of Listeria, Enterococcus, Bacillus,
and Staphylococcus(47). There are even some gram-negative bacteria such as Morayella
catarrhalis, Neisseria gonorrhea, and N. meningitidis that have been found to be
sensitive to nisin and microbisporicin (27). What is remarkable about lantibiotics is the
fact that they are active in nanomolar concentrations versus micromolar concentrations
required by some well-known antibacterial compounds.
There are three main mechanisms for lantibiotics' antibacterial activity: lipid II
mediated pore-formation, transmembrane pore-formation, and abduction of lipid II from
its physiological domain. Experiments that utilized NMR revealed that nisin forms a
highly stable complex with lipid II. This complex consists of eight nisin molecules to
four lipid II and involves the interaction between the N-terminal portion of nisin (rings A
and B) with the pyrophosphate (peptidoglycan MurNAc) and the first isoprene of lipid II.
This interaction results in lipid II being trapped in a pyrophosphate cage that makes up
the stable pore (Figure 1.5A) (82).
Solid state NMR and efflux experiments with subtilin demonstrated that it also
interacts with lipid II in the same manner as nisin (83). Epidermin, gallidermin, and
mutacin 1140 have also been shown to interact with lipid II; however, there has been no
evidence that they produce pores (4, 62). The absence of pore forming activity may be
due to the fact that they are shorter than nisin (epidermin 22 amino acids, nisin 34). In the
absence of lipid II but presence of anionic phospholipids, nisin was shown to form a tight
association with the membrane surface. This leads to a high local concentration of the
peptide which in turn causes the disruption of the lipid dynamics near the polar head
group/water interface. When the transmembrane electric potential exceeds the threshold
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level, nisin re-orientates from surface bound to a membrane-inserted configuration. The
co-insertion of the bound anionic phospholipids results in bending of the lipid surface
yielding a wedge-like, non-specific pore (Figure 1.5 C) (84). This type of pore has been
reported for subtilin and pep5 and result in the efflux of small molecules like potassium
and amino acids leading to the arrest of cellular biosynthesis (85, 86).
Although there has not been as much research conducted on the mode of action of
type A (II) lantibiotics, evidence has been obtained that shows that membrane disruption
though transmembrane pore formation is the main method used. Experiments showed
that streptococcin A-FF22 forms unstable pores with a membrane potential of at least
100mV which results in the impairment of ATP production ultimately leading to cell
death (87). Other type A (II) lantibiotics like lacticin 481 and nukacin ISK-1 also form
these unstable pores as evident in experiments involving artificial lipid monolayers which
revealed their affinity for zwitterionic and anionic lipids, respectively (88, 89). As the
members of the lacticin 481 group are so closely related in sequence and structure it can
be inferred that the same mechanism of activity exist for the other group members but
further experiments must be conducted to support this hypothesis.
Abduction of lipid II from the site of new cell wall synthesis is a novel
bactericidal mechanism that has been reported for both nisin and mutacin 1140 (Figure
1.5 B). Using confocal fluorescence microscopy, it was shown that fluorescent labeled
nisin and mutacin 1140 induced clustering of lipid II into large patches in both membrane
vesicles and in vivo membranes. Not only was lipid II bound in these clusters in vivo, but
it was dispersed everywhere except for in the septum where it was needed (3).
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Figure 1.5
Modes of Activity for Type A Lantabiotics
A.In the presence of lipid II, type A lantibiotics aggregate together using lipid II as a
docking molecule to form short lived pores. Type A lantibiotics also abduct lipid II that is
localized in the membrane from the site of new cell wall synthesis causing an efflux of
ions and leading to cell death B. In the absence of lipid II but the presence of anionic
phospholipids, a lantibiotic can become tightly bound to the membrane surface causing a
high local concentration. When the transmembrane electrical potential exceeds the
threshold, the molecules adapt a membrane-inserted conformation leading to the bending
of the lipid surface (84) C. Green bars/arches represent lantibiotics while red filled circles
represent lipid II.

Mutagenesis of Type A Lantibiotics
Mutagenesis studies were performed on various type A(I) and (II) lantibiotics in
order to better understand their function and structure as it relates to bactericidal activity
(Tables 1.3 and 1.4). In order to determine the effect of each mutation, the minimum
inhibitory concentrations (MICs) against various species of gram-positive bacteria and
overlay assays were performed. Their possible therapeutic and industrial applications lead
researchers to focus on mutations that could possible increase their bactericidal activity.
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In short, the majority of the mutants generated showed a decrease or total loss of
antimicrobial activity. This loss of activity is attributed to either the disruption of
thioether bridge formation causing a loss of detectable production by HPLC and/or
secretion or steric hindrance of the proper conformation (61, 90). Refer to Table 1.3 for a
list of mutations and their effects on nisin, gallidermin, and pep5.
Nisin is composed of five rings (A-E) and a flexible hinge region (residues 20-22)
and is the most extensively studied type A (I) lantibiotic (Figure 1.4). It has been
discovered that rings A and B are the lipid II binding domain of nisin. It is this region of
the peptide that forms a pyrophosphate cage with lipid II during pore formation (82). This
explains why so many studies have focused more on rings A and B.
Several mutations to ring A were performed such as, Alas3Abus, Dha5Ala, and
Ile4Ser5Lys6 to KFI, or VFG (91-93). When Ser3 is substituted for a threonine a βmethyllanthionine is produced in ring A resulting in dramatically decreased antimicrobial
activity. This reduction in activity is thought to be due to the loss of affinity for lipid II
since pore forming concentrations were unchanged (92). When Ser5 is replaced with Ala
the mutant shows similar antimicrobial activity as the wild-type, but drastically decreased
activity in inhibition of spore outgrowth (91). This result suggests that Dha, the residue
formed when Ser is dehydrated, is essential for inhibiting spore outgrowth, and that
antimicrobial activity and spore growth inhibition have separate mechanisms. Contrary to
the results from the previous experiment, it was discovered that when Ser is substituted
for Phe (as is the case with the KFI and VFG mutants) the spore outgrowth inhibition was
enhanced refuting the idea that Dha is needed for this activity (93).
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Ring B mutants that replaced Gly10 with Ser, His, or Ala showed as much as a
three-fold decrease in activity suggesting that bulky mutations at this position are not
well tolerated (93). This could be caused by the hindrance of dehydration to Thr at
position 8, thus opening/eliminating ring B. It was shown that for activity to be
maintained, small amino acids are required at position 10 in ring B with Pro being
preferred at position 9 (93).
Several other mutations provided evidence of the necessity of charged residues at
certain positions. No decrease in activity was seen when Lys12 was replaced with Pro,
which reduces the overall charge of nisin (92). This suggests that a positive charge at this
position is not essential for the antimicrobial activity of nisin. Likewise, the replacement
of Lys22 with either Thr or Ser resulted in similar and enhanced activity signifying that a
charged residue is not needed at this position for pore formation to occur (94). However,
it was shown that replacing Met17 with Lys results in a 2-fold decrease in activity (95).
These results show that a charged residue is not tolerated in the central segment of the
peptide.
Mutations in gallidermin at amino acid positions directly involved in thioether
formation resulted in the complete loss of production. This was seen with mutations in
which Ser3 was replaced with Asp, Ser19 was replaced with Ala, and Cys22 was deleted
(90). Even mutations that indirectly interfered with thioether bridge formation were not
tolerated as Gly10Glu and Tyr20Gly mutants were not produced in detectable amounts
(90). It is believed that this is a result of steric hindrance that disrupts the β-turn type II
conformation of the peptide (90). As gallidermin is similar to nisin, it was once believed
that pore formation was its only mode of action. As previously mentioned, this were
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proven to be untrue (4, 62). Mutations at position 12 from Ala to Lys was shown to
disrupt pore formation for Lactococcus lactis while still having activity against
staphylococci and micrococci species offered further evidence that pore formation does
not contribute to gallidermin’s antimicrobial activity (62).
Rings A and B were found to be important for both pore formation and
stabilization against proteases for pep5 (96). Mutations to pep5 at positions 27 and 33
eliminated rings B and C, respectively. This resulted in a total loss of activity and
increased sensitivity to proteolytic activity (96). When an Ala19 to Cys mutant was
generated it introduced a new thioether ring which decreased its proteolytic sensitivity
but caused a total loss of activity, presumably due to its restriction on the flexibility of the
central part of the peptide (96). Likewise, mutations where Dhb at positions 16 and 20
were replaced with Ala resulted in a significant decrease in antimicrobial activity due to a
steric hindrance of the helical conformation of pep5. From this data it was concluded that
the flexibility and helical conformation of pep5 is essential for pore formation (96).
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Table 1.3
Site Directed Mutagenesis Studies of Some Type A (I) Lantibiotics
Mutations

Bactericidal Effect
Nisin A/Z

Ile1Trp

Slightly decreased activity

Ile1Cys
Dhb2Val
Dhb2Ala
Dhb2Dha
AlaS3AbuS
Ile4Cys
Glu4Ile/Ser5Ala
Dha5Dhb
Dha5Cys
Dha5Ala
Leu6Cys
I4S5L6-SFV
I4S5L6-LFQ
I4S5L6-FFL
I4S5L6-FFS
I4S5L6-FFY
I4S5L6-FVS
I4S5L6-FVW
I4S5L6-FSF
I4S5L6-SFF
I4S5L6-FAF
I4S5L6-LSF
I4S5L6-LFA
I4S5L6-FSI
I4S5L6-IFS
I4S5L6-FLI
I4S5L6-VGG
I4S5L6-KSI
I4S5L6-KFI
I4S5L6-VFG
I4S5L6-FLS
I4S5L6-TKI
I4S5L6-FFV
I4S5L6-YQI
Pro9Ser/Gly10Ser

Dramatically decreased activity
Similar activity
Similar activity
Increased activity
Dramatically decreased activity
Dramatically decreased activity
Slightly decreased activity
Similar activity
Dramatically decreased activity
Similar activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Slightly decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Similar and enhanced activity
Similar and enhanced activity
Similar and enhanced activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
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Reference
(33, 89, 92, 97101)
(102)
(95)
(95)
(92, 95)
(92)
(102)
(45)
(91, 103-107)
(102)
(91, 104, 107)
(102)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)
(93)

Table 1.3 continued
Mutations

Pro9Thr/Gly10Ser
Pro9Ala/Gly10Ala

Bactericidal Effect

Pro9Gly/Gly10Ser

Dramatically decreased activity

Met21Cys
Asn20Pro/Met21Pro
Asn20Pro
Asn20Glu
Asn20Val
Asn20His
Asn20Gln
Asn20Phe
Asn20Lys/Met21Lys
Asn20Phe/Met21Leu/
Lys22Gln
Met21Glu
Met21Val
Met21Gly
Met21Lys
Met21His
Lys22Thr
Lys22Ser
Lys22Glu
Lys22Gly
Lys22His
Asn20Ala/Met21Lys/DhbLys22Gly
Asn27Lys
His31Lys31
His31Cys
Val32Trp

Dramatically decreased activity
Slightly decreased activity
Similar and enhanced activity
Dramatically decreased activity
Dramatically decreased activity
Slightly decreased activity
Slightly decreased activity
Slightly decreased activity
Slightly decreased activity
Slightly decreased activity

(93)
(93)
(93)
(93)
(93)
(93)
(92)
(95)
(102)
(95)
(89, 97, 98, 100,
101)
(102)
(95)
(94)
(95, 108)
(95, 108)
(95, 108)
(95, 108)
(95, 108)
(95, 108)
(95, 108)

Dramatically decreased activity
Similar and enhanced activity
Slightly decreased activity
Slightly decreased activity
Slightly decreased activity
Similar and enhanced activity
Similar and enhanced activity
Dramatically decreased activity
Slightly decreased activity
Slightly decreased activity
Dramatically decreased activity

(95, 108)
(94)
59
(95, 108)
(95, 108)
(94)
(94)
(95, 108)
(95, 108)
(95, 108)
(95, 108)

Similar activity
Similar activity
Dramatically decreased activity
Slightly decreased activity

(106)
(106)
(102)
(19, 97, 98, 100,
101)

Gly10Ser
Gly10His
Gly10Ala
Lys12Pro
AbuS13Cys
Met17Cys
Met17Lys
Met17Trp

Dramatically decreased activity
Dramatically decreased activity

Reference

Similar Activity
Dramatically decreased activity
Dramatically decreased activity
Similar Activity
Dramatically decreased activity
Dramatically decreased activity
Similar activity
Slightly decreased activity
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Table 1.3 continued
Mutations
Val32Cys
Ser33Cys
Lys34Cys
Ser3Asn
Lys6Gly
Lys6Val

Bactericidal Effect

Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity

Gallidermin/Epidermin

Reference
(102)
(102)
(102)

(90)
(90)
(62, 90)

Gly10Glu
Ala12Leu
Dhb14Dha
Dhb14Pro or Ser
Ser19Ala
Tyr20Gly
delCys21
delCys22

No activity
Slightly decreased activity
Enhanced-Dramatically decreased
activity
No activity
Dramatically decreased activity
Similar activity
Dramatically decreased activity
No activity
No activity
No activity
No activity

Dhb16Ala
Lys18Ser
Ala19Cys
Dhb20Ala
Cys27Ala
Cys33Ala

Dramatically decreased activity
Minimally decreased activity
No activity
Dramatically decreased activity
No activity
Minimally decreased activity

(96)
(96)
(96)
(96)
(96)
(96)

Pep5

(90)
(62, 90)
(90)
(90)
(90)
(90)
(90)
(90)

Terms used to gauge bactericidal activity are defined as: dramatically decreased; ≥50%
loss of activity, slightly decreased; 49-21% loss of activity, minimally decreased; ≤ 20%
loss of activity, and similar; ≤5% loss of activity. Activity was determined by comparing
zones of inhibition to wild-type. Mutations showing increased or enhanced activity
compared to wild-type are in green print. Lys18Ser for pep5 resulted in the formation of a
Dha residue.

The mutagenesis of lacticin 481, mutacin I, and nukacin ISK-1 is shown in Table
1.4. The mutagenesis study for lacticin 481 was performed in the hopes of producing
variants with enhanced bioactivity and improved therapeutic properties. Unlike the
conventional mutagenesis previously mentioned where natural amino acids were used,
this study used nonproteinogenic amino acids (N-butylglycine, sarcosine, 4cyanoaminobutyric acid, etc.) to make their lantibiotic analogues (109). From this study it
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was discovered that ring C is amendable to alterations where there were non-natural side
change substitutions (Trp19Nal, Phe21Pal, and Phe23hPhe) since all of the mutations
resulted in improved bactericidal activity (109). However, mutations like Asn15β3-Arg,
Met16N-Nle, Met16β-Ala, and Asn15β3-Arg, which contain substitutions with altered
amide backbones, resulted in a 16-34 fold decrease in activity, signifying the importance
of maintaining the structural conformational of lacticin 481 (109). Similarly, any
mutations of the N-terminal residues led to a dramatic decrease in activity (109). Lacticin
481 uses pore formation as its killing mechanism; therefore, it would be expected that
any alterations that disrupt the rings, possible binding domains, or cause major
conformational changes would result in inactivity.
When considering mutacin II, it was discovered that deletion of Asp at position 1
or replacement of Thr10 with Ala results in a complete loss of secretion indicating that
they may be crucial for certain steps in the biosynthesis pathway (110). To further support
the idea that the thioether bridges are important for activity, mutations were made where
Cys15 or Cys26 where replaced with Ala, resulting in a loss of activity (110). A mutation
where Cys27 was replaced with Ala showed a dramatic decrease in antimicrobial activity
and secretion, suggesting its importance in activity and possibly proper folding and
recognition by the exporting system (110). Tandem mass spectrophotometry of the
Cys15Ala mutant confirmed that the Thr at position 10 was dehydrated (110).
As the Thr10Ser mutant is as active as the wild-type, it was concluded that a didehydro
amino acid is needed at this position and that the biosynthesis machinery does not
discriminate between threonine and serine (110).
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A bank of nukacin-ISK1 mutants were generated and evaluated. The largest
collection of mutants with increased activity where produced in this experiment. Once
again it was shown that any disruption to the ring structures result in a complete loss of
activity (111). It was also discovered in this study that Gly5 and His12 (conserved
residues in type A (II) lantibiotics), Asp13, Met16, Asn17, and Gln20 are all essential for
bactericidal activity (111). It was also determined that the charged residues, Lys 1-3, in
the N-terminal are amendable to small, nonpolar, hydrophobic, or uncharged polar amino
acids but that negatively charged residues resulted in a loss of bioactivity (111). This
could be due to a repulsion effect between the lantibiotic and its target lipid II. Further
evidence to support the notion that certain residues are important for target binding was
demonstrated when Val at position 22 was replaced with Ile resulting in an increased
bioactivity that is believed to be contributed to Ile ability for a higher hydrophobic
interaction with lipid II (111) . Another mutant, Asp13Glu, is believed to cause an
increased affinity for lipid II thus explaining its increased antimicrobial activity (111).
Other mutants such as Val10Leu and Phe21Trp were produced in lower concentrations
than the wild-type but showed larger zones of inhibition due to their increased solubility
(111).
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Table 1.4
Site Directed Mutagenesis Studies of Some Type A (II) Lantibiotics
Mutations

Bactericidal Effect
Lacticin 481

Reference

Gly2,3,5β-Ala
Gly5Sar
Gly5Acpc
Val6D-Val
Glu13Cba
Asn15β3-Arg
Met16N-Nle
Met16β-Ala
Trp19Nal
Phe21Pal
Phe23hPhe

No activity
Dramatically decreased activity
Dramatically decreased activity
No activity
No activity
Dramatically decreased activity
No activity
Dramatically decreased activity
Increased activity
Increased activity
Increased activity

(109)
(109)
(109)
(109)
(109)
(109)
(109)
(109)
(109)
(109)
(109)

delAsn1
Val7Ala
Pro9Ala
Thr10Ala
Thr10Ser (Dhb-Dha)
Cys15Ala
Cys26Ala
Cys27Ala

No activity
Similar activity
Dramatically decreased activity
No activity
Similar activity
No activity
No activity
Dramatically decreased activity

(110)
(110)
(110)
(110)
(110)
(110)
(110)
(110)

Lys1: G, A, L, I, S, N, or R
Lys1Met
Lys1Phe
Lys1Glu
Lys2Gly
Lys2Ala
Lys2Val
Lys2Leu
Lys2Ser
Lys2Asn
Lys3Gly
Lys3Ala
Lys3Trp
Lys3Ser
Lys3Arg
Lys3Glu
Lys3Asp

Slightly decreased activity
No activity
No activity
No activity
Slightly decreased activity
Similar activity
No Activity
Slightly decreased activity
Similar activity
Similar activity
Similar activity
No activity
Similar activity
Similar activity
Similar activity
No activity
No activity

(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)

Mutacin II

Nukacin ISK-1
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Table 1.4 continued
Mutations

Ser4: G, A, V, Q, or R
Ser4Leu
Ser4Thr
Ser4Glu
Ser4Asp
Gly5: A, V, L, I, P, Y, F, S, T,
H,
Gly5Trp
Val6: G, Y, S, R, E, or D
Val6Ala
Val6Met
Val6Trp
Val6Phe
Ile7: G, A, P, C, S, K, or R
Ile7Val
Ile7Met
Ile7Phe
Pro8Gly
Pro8Ala
Pro8Ser
Pro8Gln
Pro8Val
Pro8: I, M, C, Y, W, F, H, R,
or E
Val10: A, Y, W, S, or T
Val10Leu
Val10Ile
Val10Pro
Val10Met
Val10Cys
His12: G, A, V, L, M, C, W,
F, S, Q, E, or D
His12Lys
Asp13: G, A, V, L, M, W, F,
Q, N, or R
Asp13Glu
His15Gly
His15Val
His15Leu
His15Phe
His15Ser

Bactericidal Effect

Reference

Dramatically decreased activity
No activity
Similar activity
Dramatically decreased activity
Dramatically decreased activity
Dramatically decreased activity
No activity
Similar activity
Dramatically decreased activity
Slightly decreased activity
No activity
Similar activity
Similar activity
Similar activity
Slightly decreased activity
Dramatically decreased activity

(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)
(111)

No activity
Increased activity
Similar activity
Increased activity
Slightly decreased activity
Dramatically decreased activity
No activity

(111)
(111)
(111)
(111)
(111)
(111)
(111)

Dramatically decreased activity
No activity

(111)
(111)

Increased activity
Similar activity
No activity
Slightly decreased activity
Increased activity
Increased activity

(111)
(111)
(111)
(111)
(111)
(111)

Similar activity
Slightly decreased activity
Increased activity
Slightly decreased activity
Slightly decreased activity
No activity
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(111)
(111)
(111)
(111)
(111)
(111)

Table 1.4 continued
Mutations
Met16: G, A, V, P, W, S, T,
Q, N, K, R, or D
Met16Leu
Asn17: G, V, W, F, S, T, Q,
R, E, or D
Gln20: G, C, Y, W, F, S, T,
or R
Gln20Ala
Phe21Trp
Val22Ile
Thr24Gly
Ser27Pro

Bactericidal Effect
No activity

Reference
(111)

Similar Activity
No activity

(111)
(111)

No activity

(111)

Similar activity
Increased activity
Increased activity
Increased activity
No activity

(111)
(111)
(111)
(111)
(111)

Terms used to gauge bactericidal activity are defined as: dramatically decreased; ≥50%
loss of activity, slightly decreased; 49-21% loss of activity, minimally decreased; ≤ 20%
loss of activity, and similar; ≤5% loss of activity. Activity was determined by comparing
zones of inhibition to wild-type. Abbreviations used are: Sar: sarcosine, Acpc:
aminocyclopropanic acid, Cba: 4-cyanoaminobutyric acid, β3-Arg: β3 homoarginine, NNle: N-butylglycine, Nal: naphthylalanine, Pal: 4-pyridynylalanine, and hPhe:
homophenylalanine. Mutations with increased activity compared to the wild-type are in
green print.

Applications of Type A Lantibiotics
Lantibiotics have several commercial applications with food preservative being
the most applied to date. This is due to their broad spectrum of activity against foodborne pathogenic and spoilage bacteria, as well as pH and heat tolerance. They are also
inactive and non-toxic to eukaryotic cells. They can be inactivated by digestive proteases
so there is little effect on the gut microflora. To date, there has been no cross resistance
with other antibiotics (112). Also, the genes that encode for lantibiotic synthesis can be
easily manipulated and/or transferred to produce starter cultures with desired traits (113).
To date, nisin is the only type A (I) lantibiotic used as a food preservative. It was
first introduced as a food preservative in processed cheese in the UK over 50 years ago
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(E239) and is now recognized as a safe food preservative in over fifty countries (114).
The trials in the UK used a cocktail of Clostridium spp. spores (200 spores/g) in
processed cheese products and found that nisin prevented spoilage during storage at 37°C
at a concentration of 6.25µg/g (113). The study also found that nisin can delay or prevent
the growth and subsequent toxin formation by C. botulinum type A and B at a
concentration of 12.5µg/g and higher (113). Nisin has also been found to increase the
shelf life of pasteurized dairy products and desserts and is effective in providing
protection against B. cereus in liquid egg products (114, 115). Canned foods have the
potential of being contaminated with a variety of spore forming bacteria that can lead to
spoilage and human infections. Nisin has been shown to prevent spoilage and prolong
storage of canned vegetables that are either low-acid or high-acid by controlling the
growth of B. stearothermophilus, C. thermosaccharolyticum, B. macerans, B. coagulans,
and C. pasteurianum (114). Since nisin has no effect against yeast but is active against
lactic acid bacteria (LAB), it has been used to control spoilage caused by LAB in the
production of alcoholic beverages (113). Nisin has even been utilized in the production of
salad dressing by controlling the growth of LAB at concentrations ranging from 2.55mg/L (113). In the Netherlands, the genes responsible for nisin production and immunity
were transferred to industrial strains by conjugative transfer (113). The strains were then
tested and concentrated to be used as pure starter cultures to produce Gouda cheese that
was protected against C. tyrobutyricum and S. aureus (113).
Experiments were also performed to determine nisin’s effectiveness in
combination with other components. It was discovered that chelating agents such as
lysozyme, sodium lactate, acetic acid, etc. can be used to pre-treat gram negative bacteria
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and make them more sensitive to nisin (112). Unlike nisin’s success in being useful in
producing dairy products and alcoholic beverages, it was discovered that it has some
limitations in meat products due to its interaction with phospholipids, poor solubility at
pH above 6, and inactivation by the formation of a nisin-glutathione adduct (116). To
overcome these limitations, nisin was investigated in combination with various
components. Nisin with nitrite were found to delay botulinal toxin formation in meat
systems and showed an increased activity on clostridia endospores outgrowth and also on
Leuconstoc mesenteriodes and L. monocytogenes, serious life threatening pathogens (117119). Likewise a nisin-containing cellophane coating reduced viable counts of total
aerobic bacteria by 1.5 fold in fresh veal stored at 8°C (120). Other methods/techniques
have been employed in combination with nisin to overcome its limitation in meat
systems. Ultrahigh hydrostatic pressure, pulsed electric field, and modified atmosphere
packaging have all been used in combination with nisin and have resulted in the control
of outgrowth of L. monocytogenes, E. coli, and S. typhimurium in meat systems (112,
121).
Lantibiotics also have some veterinary and biomedical applications that are
useful. In terms of their veterinary uses, nisin and gallidermin have been shown to be
useful in the treatment of bovine mastitis, a disease that causes inflammation of the udder
due to an infection with Staphylococcus aureus, S. epidermidis, or streptococci (122).
Several commercial products, Consept© (a teat dip) and Wipe-out© (a teat wipe),
containing nisin/gallidermin have been developed (122). Streptococcus mutans which
produces mutacin 1140 was genetically engineered to both have a replacement of the
gene responsible for producing lactate dehydrogenase, the enzyme responsible for lactic
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acid production by the bacteria, and increase its production of mutacin 1140 (123). Lactic
acid is produced as a by-product from sugar digestion by wild-type S. mutans. This acid
is capable of demineralizing tooth enamel and dentin causing cavities. Since the effector
strain is able to produce larger amounts of mutacin 1140, it is able to displace wild-type
S. mutans and colonize the oral cavity (123). This replacement results in a decrease of
cavities as the effector strain does not produce a harmful acid.
An example of the biomedical potential of lantibiotics is exemplified in the
utilization of gallidermin and epidermin in the treatment of acne, eczema, folliculitis, and
impetigo and their subsequent addition to various topical medications for these conditions
(88). Salivaricin A2 and B producing strain, Streptococcus salivarius K12, is employed as
a probiotic ingredient in mouth wash and throat lozenges world-wide to protect against
Streptococcous pyogenes (124). Microbisporicin has some potential as a new antibiotic
therapy as it is active against MRSA and enterococci (27). Nisin has no known human
toxicity and has long since been considered a safe food additive. Therefore, the use of
nisin as a possible antibiotic therapy is plausible. Nisin has been found to be successful in
the treatment of enterococcal infections, methicillin-resistant Staphylococcus epidermidis
(MRSE), penicillin-resistant Streptococcus pneumoniae, and VRE (in combination with
ramoplanin, a cell wall peptidoglycan inhibitor) (122, 125-128). Nisin is believed to also
be useful for the treatment of antibiotic associated diarrhea as it prevents in vitro
germination of clostridia endospores produced by Clostridium difficile (129). This
bacterium can cause pseudomembranous colitis, a severe infection of the colon.
However, further research is required before nisin can be successfully used as a treatment
as it is sensitive to digestive enzymes. Nisin was also found to be effective in the
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treatment of peptic ulcer as it is active against the causative agent, Helicobacter pylori,
with the aid of a chelator (113, 122). Nisin can be useful for this therapy because it is
active at a low pH, insensitive to pepsin, but easily degraded by pancreatic proteases
eliminating the possibility of gastrointestinal side effects (113). Nisin has also been
shown to inhibit sperm motility and thus can be implemented into contraceptive products
to both prevent pregnancy and protect against STDs (130).

Mutacin 1140
This dissertation will be focusing on the lantibiotic, mutacin 1140. Mutacin 1140
is a type A (I) lantibiotic produced by Streptococcus mutans JH1140. Its rings A and B,
the lipid II binding domain, are similar to nisin. Rings A and B and only differ at position
4 where there is an Ile for nisin and Trp for mutacin 1140 (Figure 1.4 and 1.6B). Since the
lipid II binding domain of mutacin 1140 is so similar to nisin, it was once believed that it
too formed pores. However, research revealed this idea to be incorrect (4). In fact, a
study that used confocal fluorescence microscopy of fluorescently labeled mutacin 1140
showed that it induced clustering of lipid II into large patches in both membrane vesicles
and in vivo membranes (3). The bound lipid II was dispersed everywhere throughout the
membrane and no longer localized at the septum where it is needed for cell division. This
results in a loss of cell membrane integrity that ultimately leads to cell death(3).
Since mutacin 1140 and mutacin III are so similar, it is possible to use mutacin
III’s biosynthesis gene cluster (Figure 1.6A) as a blueprint for mutacin 1140. In this gene
cluster, all of the enzymes needed to produce a mature mutacin 1140 peptide are present.
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This includes mutD, the gene that produces the enzyme responsible for the
decarboxylation of the C-terminal cysteine to yield mutacin 1140’s characteristic AviCys
(Figure 1.6B).

Figure 1.6
Biosynthesis Gene Cluster and Covalent Structure of Mutacin 1140
The biosynthesis gene cluster for mutacin III taken from Streptococcus mutans UA787,
accession no.AF154675. Prepropeptide: white, modification enzymes: grey horizontal
stripes, protease: solid grey, transporter: grey vertical stripes, and regulator: grey brick
(A) The covalent structure of mutacin 1140 (B) shows the ring numbering and highlights
the lipid II binding domain.

Mutacin 1140 has many beneficial applications that are presently being
investigated. An engineered strain of Streptococcus mutans was created. Its lactic acid
gene was replaced with alcohol dehydrogenase, and is capable of producing more
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mutacin 1140 than wild-type S. mutans (123). The elevated production of mutacin 1140
allows the effector strain to colonize the oral cavity more efficiently. The strain is then
able to displace the wild- type S. mutans in the oral cavity (123). Since then the strain has
been modified by deleting the dal gene needed for D-alanine biosynthesis and the comE
gene which is needed for genetic transformation (131). This new strain, A2JM, was
produced to allow rapid removal, should any deleterious effects arise, through daily use
of chlorhexidine-aaaaa (131). Deletion of the comE gene allowed the strain to have a
lower rate of transformation (131). This was done to be able to move forward with
clinical trials of mutacin 1140 as a replacement therapy for the prevention of dental caries
in humans (131).
Preclinical development of mutacin 1140 for the treatment of gram-positive
infections is also currently underway. One study tested mutacin 1140 against a wide array
of gram-positive and gram-negative bacteria, and medically important pathogens. It was
concluded that mutacin 1140 is bactericidal against S. pneumonia and multi-drug resistant
S. aureus and bacteriostatic against vancomycin-resistant Enterococcus faecium (VREF)
while it had no activity against gram-negative bacteria or yeast (132). The study also
showed that mutacin 1140’s time-kill profiles for selected pathogens were consistent with
vancomycin, the antibiotic of last resort (132). Low-level increases in MICs during
repeated cultivation of selected pathogens in the presence of sublethal concentrations
indicated that the development of significant resistance to mutacin 1140 is unlikely (132).
Since it has been established that mutacin 1140 is active against MRSA, VRSA, VREF,
and vancomycin-intermediate S. aureus (VISA), studies were conducted to ascertain its
clinical efficacy and best route of administration (132-134).
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In order to determine mutacin 1140’s potential clinical efficacy, its bactericidal
activity was tested in the presence of human serum (133). Mutacin 1140 at concentrations
ranging from 6.25-200µg/mL was bound to human serum at 92.7% ± 2.0% in a
concentration independent manner (133). The serum had an inhibitory effect on mutacin
1140’s bactericidal activity against S. pneumonia, but it enhanced mutacin 1140’s activity
against S. aureus (133). The belief is that the serum offers some type of protection for S.
pneumonia while possibly having some type of augmentation effect when considering S.
aureus. It was concluded that mutacin 1140 is potentially active in vivo against both
organisms (133).
Another study concerned itself with the pharmacokinetics, exposure-response
relationship, and pharmacokinetics/pharmacodynamics index to ascertain the best route
of administration of mutacin 1140 for maximum therapeutic effect (134). It was
determined from this study that a slow infusion works best as it increases the time the
concentrations remain above the MIC while minimizing the hypersensitivity response
seen when administered rapidly (which also occurs when vancomycin is given rapidly)
(134).
Mutacin 1140’s similarity to both nisin and gallidermin, which can be purchased
commercially, lack of extensive research, and therapeutic potential make it the ideal
lantibiotic to be further explored. The purpose of this dissertation is to use mutacin 1140
and other closely related lantibiotics such as nisin and gallidermin, to investigate both
chemical modification capability and structural integrity of type A (I) lantibiotics. This
will encompass determining the effects of oxidation on bioactivity and utilizing the
Dha/Dhb residues for visualization of the peptide in vivo. Also, the Dha/Dhb residues
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will be utilized to ascertain their amenability. Experiments will also be conducted to
investigate the importance of the lanthionine rings and various amino acid residues.
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CHAPTER II
OXIDATION OF LANTHIONINES RENDER THE LANTIBIOTIC NISIN INACTIVE

Note
The work presented in this chapter was published in Applied and Environmental
Microbiology 75(5), 1381–1387 (2009) and Biochemistry 47(10), 3308-3314 (2008).
Mass spectrometry work was performed by Kristina Håkansson and Anastasia Kalli at the
University of Michigan. I would like to thank Eefjan Breukink from Utrecht University
who supplied lipid II as a gift. I would also like to thank both William Monroe and
Amanda Lawrence at the Electron Microscopy Facilities at Mississippi State University
for their services.

Abstract
The peptide antibiotic nisin A belongs to the group of antibiotics called
lantibiotics. They are classified as lantibiotics because they contain the structural group
lanthionine. Lanthionines are composed of a single sulfur atom that is linked to the βcarbons of two alanine moieties. These sulfur atoms are vulnerable to environmental
oxidation. A mild oxidation reaction was performed on nisin A to determine the relative
effects it would have on bioactivity. High-mass-accuracy Fourier transform ion cyclotron
resonance mass spectrometry data revealed the addition of seven, eight, and nine
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oxygens. These additions correspond to the five lanthionines, two methionines, and two
histidines that would be susceptible to oxidation. Subsequent bioassays revealed that the
oxidized form of nisin A had a complete loss of bactericidal activity. In a competition
study, the oxidized nisin did not appear to have an antagonistic effect on the bioactivity
of nisin A, since the addition of an equal molar concentration of the oxidized variant did
not have an influence on the bactericidal activity of the native antibiotic.
Electron microscopy data revealed that the oxidized forms were still capable of
assembling into large circular complexes, demonstrating that oxidation does not disrupt
the lateral assembly mechanism of the antibiotic. Affinity thin-layer chromatography and
fluorescence microscopy experiments suggested that the loss of activity is due to the
inability of the oxidized form of nisin A to bind to the cell wall precursor, lipid II. Given
the loss of bioactivity following oxidation, oxidation should be an important factor to
consider in future production, purification, pharmacokinetic, and pharmacodynamic
studies.

Introduction
Lantibiotics are ribosomally synthesized peptide bacteriocins that undergo
extensive posttranslational modifications to yield unusual amino acids, like lanthionine,
methyllanthionine, 2,3-didehydroalanine, 2,3-didehydrobutyrine, and S[aminovinyl]cysteine (1). The name lantibiotic is derived from the presence of the
posttranslationally modified lanthionine residues. Nisin A (3351.5 Da), produced by
Lactococcus lactis, belongs to this class of antibiotics and is further sub-classified as a
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type A (I) lantibiotic. Type A (I) lantibiotics are cationic and have a rigid ring
conformation separated by areas of flexibility. Another well-studied lantibiotic,
gallidermin, also belongs to this class of lantibiotics and has significant homology to
nisin A in the first two lanthionine rings, A and B (Figure 2.1).

Figure 2.1
Schematic Drawing of the Covalent Structure of Nisin A and Gallidermin
The N-terminal rings A and B are believed to be responsible for binding lipid II.

The antibiotics in this class have drawn considerable attention for their
bactericidal potential as preservatives and for their potential for treating Staphylococcus
and Streptococcus infections. Nisin A has been used for over 40 years in Europe as a
preservative in the food industry and was approved for use in the United States by the
FDA in 1988. Its uses include controlling the growth of various bacteria in pasteurized
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cheese and liquid egg ingredients, as well as preserving salad dressings (2), canned foods
(3, 4), and, most recently, ground beef (5). Other lantibiotics, including gallidermin and
epidermin, have been shown to be useful as treatments for acne and in the maintenance of
oral health (6, 7). Recent literature shows that both nisin A and gallidermin can be used to
treat and/or prevent mastitis in bovines (8, 9), and they are currently marketed as wipes.
Lantibiotics have multiple modes of bactericidal activity (10, 11). In the case of
nisin A, the sensitivity of the host bacterium has been shown to be dependent on the
charge states of its cell wall and membrane (11-13). More importantly, the bactericidal
activity is attributed to lipid II abduction (14-16). The binding motif for nisin A to lipid II
has been characterized by nuclear magnetic resonance (NMR) (17) in which the Nterminal portion of nisin A, lanthionine rings A and B, interacts with the pyrophosphate,
the peptidoglycan MurNAc, and the first isoprene of lipid II.
A novel mechanism of antimicrobial activity for nisin A and mutacin 1140, a
lantibiotic produced by Streptococcus mutans whose rings A and B are similar to nisin,
has been described. This mechanism involves binding to lipid II and sequestering it into
large complexes. These complexes aid in the abduction of lipid II from the growth zones
of bacteria, where lipid II is required for new cell wall formation (18). In order to have
this clustering affect it is assumed that there would have to be some type of lateral
assembly mechanism involved as a single monomer of mutacin 1140 or nisin could not
be responsible for the abduction of lipid II. This assumption is further supported by the
fact that through pyrene fluorescence and circular dichroism it was determined that the
nisin-lipid II pore consists of a minimum of 8 nisin and 4 lipid II molecules(19). Lateral
assembly or self-assembly of proteins into various supra-molecular structures such as
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aggregates, nanotubes, or fibrils is a widespread phenomenon in biology (17, 20-22).
Self-assembly of peptides has been exploited for many technological applications,
including acting as scaffolds for cell culture and vectors for gene and drug delivery (23,
24). They have also been used as templates for nanofabrication and biomineralization
(25, 26). This makes self-assembly an interesting characteristic to study.
An oxidized form of nisin A was characterized using bactericidal assays, highmass-accuracy Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR
MS), chromatography methods, and electron and fluorescence microscopy techniques.
The objectives of this study were to determine changes in the biophysical properties of
oxidized nisin A as they relate to its bactericidal activity, its ability to interact with
bacterial membranes, its capacity for lateral assembly, and its ability to bind to lipid II.
The hypothesis is that oxidation will have a negative effect.

Experimental Design
All media were purchased from Difco Laboratory (Detroit, MI), and chemicals
were purchased from Fisher Scientific (Pittsburgh, PA) and were the highest grade unless
otherwise stated. Micrococcus luteus (ATCC 272), Staphylococcus aureus (ATCC
25923), and Streptococcus pneumonia (ATCC 27336) were used for the bioassay studies.
Grace-Vydac C18 columns were purchased from Nest Group (Boston, MA).
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Antimicrobial Agents
Nisin A (~2.5% purity) was purchased from Sigma Aldrich (Milwaukee, WI) and
was purified as follows. The sample (500 mg) was weighed on an OHAUS Adventurer
Pro analytical balance (Pine Brook, NJ) and dissolved in 10mL of 35% acetonitrile
(ACN)-0.1% trifluoroacetic acid (TFA). Subsequently, the sample was intermittently
sonicated for 15 min (4710-UltrasonicHomogenizer; Cole-Palmer Instrument Co.),
making sure not to overheat the solution. The solution was then centrifuged (Sorval RC5B refrigerated Superspeed Centrifuge with GSA rotor; Du Pont Instruments) at 10,000
rpm for 10 min to remove any insoluble material. Nisin A was purified by reverse-phase
high performance liquid chromatography (RP-HPLC) using a 10 X 250mm C18column
(Grace-Vydac; catalog no. 201TP1010) on a Bio-Rad BioLogic F10 DuoFlow with a
Quad Tec UV-Vis Detector system. An ACN gradient was established by varying the
flow rate of solvent A (99% ACN-0.1% TFA) relative to solvent B (water-0.1% TFA),
maintaining a constant flow rate of 3.5mL/min, monitored at 220 nm. The HPLC protocol
for purification consisted of an isocratic flow (solvent B; 85%) for 5 min to equilibrate
the column before injection, followed by a 1mL injection of the sonicated nisin A
solution, and then a linear gradient (solvent B; decreased from 85% to 50% over a 30-min
period) was used to elute nisin A.
Nisin A eluted from the column at ~57% solvent B. The nisin A fractions were
pooled and concentrated on a rotary evaporator (Buchi Rotovapor R-210) to remove the
ACN before the sample was lyophilized (FTS Flexi-Dry; Warminster, PA) overnight.
Powdered nisin A samples were placed into 1.5mL eppendorf tubes, weighed, wrapped in
foil, and stored at 4°C until they were used. To determine its purity, nisin A (100µg) was
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run on an analytical C18 column (Grace-Vydac; catalog no. 201TP54) using a linear
gradient (solvent B; decreased from 95% to 30% over 30 min). The purity of nisin A was
estimated to be >95% from the chromatogram. Purified gallidermin (>95% purity) was
purchased from Alexis Biochemicals (Lausen, Switzerland).
Fluorescently labeled vancomycin and an oxidized variant of nisin A were
synthesized for confocal microscopy experiments. The unique carboxyl groups of
vancomycin and the oxidized variant of nisin A were used to attach 5-(aminoacetamido)fluorescein (Invitrogen, Carlsbad, CA). The fluorescent label was attached using a
standard coupling procedure in 100µL dimethylformamide using 50nmol peptide,
50nmol 5-(aminoacetamido)-fluorescein, and 60nmol of both N-(3dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride and 1-hydroxy-7azabenzotriazole. The reaction mixture was incubated overnight at room temperature, and
the labeled products were purified as previously reported (16).

Oxidation Protocol
Nisin A (1mg/mL) and gallidermin (1mg/mL) were dissolved in deionized water.
Oxidation of nisin A and gallidermin occurred in a1.5mL eppendorf tube containing
1,250µL of the nisin A or gallidermin solution,125µL of acetic acid (99%; Acros
Organics), and 30µL of hydrogen peroxide (30%; VWR Chemical Reagents). The
samples were mixed, capped, wrapped in parafilm, and incubated at room temperature for
approximately 16 h. The samples were dried under vacuum at room temperature (Savant
DNA 120 Speedvac Concentrator; Thermo) and resuspended in 1mL of ACN-water
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(20/80) solution.These samples were purified by RP-HPLC on a 10 X 250mm C18
column (Grace-Vydac; catalog no. 201TP1010) using the same solvent and gradient
conditions described above. The oxidized nisin A and oxidized gallidermin eluted at
~57% and ~52% solvent B, respectively.

Bioactivity Assays
A quantitative method was used to determine the MICs for nisin A and oxidized
nisin A. A 48-well polypropylene plate was used to perform a two-fold serial dilution of
nisin A (250µg/mL), oxidized nisin A (250µg/mL), and 50% ACN (negative control) in
duplicate, with 50% ACN serving as the diluting solvent. A volume of 10µL containing
50µg of antibiotic suspension was used for the initial two-fold serial dilution. Previous
experience had shown that using 50%ACN as the diluting solvent minimized nonspecific
binding of the antibiotic to the polypropylene plate. The top agar (30 g/liter Todd-Hewitt
Broth [THB] and7.5 g/liter nutrient agar) was cooled to 42°C in a water bath before the
cell suspension was added and aliquoted into the plate wells. M. luteus, S. aureus, and S.
pneumonia were grown in a 50mL tube containing 20mL of Todd-Hewitt yeast extract
(THyex) broth (30 g/liter THB and 3 g/liter yeast extract) to an optical density at 600 nm
(OD600) of 0.6. The bacterial culture was diluted100-fold in fresh THyex medium.
Subsequently, 400µL of this medium was added to 10mL of top agar to give a final
standardized concentration of ~105 CFU/ml. Aliquots of top agar (190µL) were added to
the samples in the microtiter wells, yielding a final volume of 200µL.
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The plates were then covered and incubated inverted in a candlejar at 37°C overnight.
The MIC was determined as the lowest concentration showing inhibition of visible
growth.
A deferred-antagonism assay was used for comparing the activities of gallidermin
and oxidized gallidermin, since we had a limited amount of gallidermin. However, this
assay is more sensitive than the MIC assay used for nisin but is not quantitative. M. luteus
and S. aureus were grown to an OD600 between 0.4 and 0.8 and diluted to an OD600of
0.2. Then, 400µL of these cells was added to 10ml of top agar. Five millilitersof melted
top agar containing a standardized suspension was added to each 100 X 15mm petri dish
(Fisher Scientific, Pittsburg, PA) containing approximately10mL of THyex agar (30
g/liter THB, 3 g/liter yeast extract, and 15 g/liter ofnutrient agar). Serial five-fold
dilutions of gallidermin (1µg/µL) and oxidized gallidermin (1µg/µL) were made in 100
µl of ACN/water (80/20). Once the top agar on the petri dish solidified, 5µL of each
dilution was stabbed in triplicate on the plate. The plates were allowed to dry before
being inverted and placed in a candlejar overnight at 37°C. Activity was expressed in
arbitrary units per mL, which corresponds to the reciprocal of the last dilution showing a
detectable inhibition zone against each indicator strain.

Mass Spectrometry
Experiments were performed with an actively shielded 7-T quadrupole FT-ICR
mass spectrometer (Apex-Q; Bruker Daltonics, Billerica, MA), as previously described
(33). Nisin A and oxidized nisin A were electrosprayed in positive ion mode at a flow
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rate of 70µL/hour at concentrations of 0.3µM and0.1µM, respectively. Frequency-tomass calibration was performed with an internal standard (electrospray tuning mix
G2421A; Agilent Technologies, PaloAlto, CA) using ions with m/z values of 622.0289
and 922.0098. Spectra were acquired with XMASS (version 6.1; Bruker, Daltonics) using
512,000 data points and summed over three scans. Data processing was performed with
the MIDAS analysis software (27) and Data Analysis (version 3.3; Bruker, Daltonics).

Transmission Electron Microscopy (TEM)
Negatively stained samples were prepared as previously described (28) by
floating 20µL of 20µM nisin A, oxidized nisin A, and mutacin 1140 solution (ACNwater [80:20]) on a carbon-coated copper grid for 4 minutes than stained for 30 sec with
2% uranyl acetate. Excess liquid from each sample was blotted with filter paper, and
observed under a transmission electron microscope (Jeol JEM-100CXII; JeolLtd., Tokyo,
Japan). Images were taken at magnifications between 10,000 and 40,000X.

Thin Layer Chromatography (TLC)
The mobile solvent used for the nisin A/lipid II affinity experiments was
previously described (2). The mobile solvent (solvent A) consisted of butanol-acetic acidwater-pyridine (15:3:12:10 [vol/vol/vol/vol]). Different ratios of nisin A and lipid II were
incubated for approximately 2 hours in a capped 0.2mL glass vial. The reaction mixture
consisted of 10µL of solvent A containing 0.2mM and0.8mM concentrations of nisin A
and oxidized nisin A while the concentration of lipid II was maintained at 0.068mM.
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These concentrations correspond to a 3:1and 12:1 ratio of nisin A to lipid II. The control
sample consisted of 10µL of solvent A with 0.068 mM lipid II with no antibiotic and
0.2mM and 0.8mM concentrations of nisin A and oxidized nisin A with no lipid II.
Samples were spotted on a thin-layer chromatography (TLC) plate (5 X 10cm silica gel
60F254; Merck) and air dried. Each plate was inserted into its own chamber consisting of
approximately 10mL of solution A and allowed to run until the solvent front was roughly
2-4cm from the top. The plates were then removed and allowed to air dry before being
stained in an iodine chamber. Photographs were taken using a UVP MultiDoc-It Digital
Imaging System (Upland, CA).

Confocal Laser Scanning Microscopy
Bacillus megaterium de Bary (ATCC14581) was grown at 37°C in THyex broth
(30 g/liter THB and 3 g/liter yeast extract) and was treated as previously described (18,
29). The oxidized variant of nisin A, a fluorescein-labeled oxidized variant of nisin A,
and nisin A were added to the B. megaterium cells at a concentration of 15µg/mL and
incubated for 10min at room temperature. Vancomycin:fluorescein-labeled vancomycin
(50:50) was added to the cells at a concentration of 2µg/mL for 1 min at room
temperature. The cells were washed three times with an equal volume of phosphatebuffered saline, fixed with 1.6% formaldehyde for 1 h on ice, and resuspended in
phosphate-buffered saline. The cell suspensions were applied onto a glass slide and
mixed with an equal volume of 2% low-melting-point agarose to immobilize the sample.
The immobilized B. megaterium bacteria were analyzed on a ZeissAxiovert 200 M
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inverted research microscope with a Plan-Apochromat 100x/1.40 oil objective. The
fluorescein labeled antibiotics appears green upon excitation by an argon laser (488 nm).
Phase-contrast optics was used for detection of bacteria. LSM 5 image browser software
was used for analysis of the images and control of the microscope.

Results

Characterizing the Physical Properties of the Oxidized Product
Nisin A was oxidized using peroxide under mildly acidic conditions that
improved hydrogen peroxide stability. Once nisin A was oxidized (Figure 2.2A), it was
purified using a semipreparative C18 column. The chromatograms for nisin A and
oxidized nisin A were superimposed (Figure 2.2B), showing similar retention times
following oxidation. Nisin A and oxidized nisin A both eluted around 57% solvent B.
The similar retention times for nisin A and oxidized nisin A suggest that the
hydrophobicity properties of nisin A and its intrinsic structural conformation remained
unchanged following oxidation. There was a larger flow through peak in the oxidized
nisin A sample, as well as additional unresolved peaks that eluted between 70% and 60%
solvent B. Only the 57% peaks for nisin A and oxidized nisin A were characterized in
this study.
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Figure 2.2
Oxidation of Nisin and Subsequent HPLC Chromatogram
A. Schematic drawing of the structure of nisin A following treatment with hydrogen
peroxide under acidic conditions. The gray shading represents amino acid residues that
were most likely to be oxidized. B. Superimposed RP-HPLC chromatogram of nisin A
(black) and oxidized nisin A (grey).

MS was done to ascertain the physical properties of the molecules. High-massaccuracy FT-ICR MS data showed +4,+5, and +6 charge states for nisin A and oxidized
nisin A (Table 2.1). For nisin A, the signal-to-noise (S/N) ratios were 7.3, 28.9, and 14.3
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for the +4, +5, and +6 charge states, respectively, while the S/N ratios were 4.9, 28.3, and
33.9, respectively, for the +4, +5, and +6 charge states of oxidized nisin A. The high S/N
ratios observed suggest that both nisin A and oxidized nisin A ionize efficiently. The
purified (native) nisin A sample was shown to contain singly oxidized variants of nisin A
and therefore demonstrated precedence for naturally occurring oxidation. However, the
peak corresponding to a single oxidation is a mixture of the oxidized species and the
addition of water. The oxidized nisin A sample has 7, 8, and 9 additions of oxygen. As
predicted by the nature of the chemistry used to oxidize nisin A, the data show that the
thioether linkages remain intact following oxidation. Breakage of the thioether linkages
following oxidation would result in an increase in mass of 18.015 Da per thioether
linkage due to an addition of oxygen and two hydrogens and not in an increase in mass of
15.999Da per thioether linkage as observed in the FT-ICR MS data. An increase in
15.999 Da represents the addition of a single oxygen per thioether linkage. The residues
that would be susceptible to oxidation with hydrogen peroxide are the five lanthionine
rings, two methionines, and two histidines. The thioether linkages in the lanthionines
would be converted to sulfoxides, the methionine would be converted to methionine
sulfoxide, and the histidine would be converted to 2-oxo-histidine. Based on relative ion
abundances of monoisotopic peaks (normalized to the charge state), approximately 48%
of oxidized nisin A contains an addition of seven oxygens and about 39% has an addition
of eight oxygens. An addition of nine oxygens was observed for a smaller proportion of
oxidized nisin A, approximately 14%.
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Table 2.1
FT-ICR Mass Spectrometry Chart of Purified Nisin A Ions and Oxidized Nisin A Ions
Calibrated m/z
Nisin A
838.8937
842.8979
671.3160
674.5156
559.5969
562.2633
Oxidized Nisin A
870.8829
866.8871
700.1053
696.9081
693.7086
583.5888
580.9234
578.2581

Theoretical
m/z

Error in
ppm

Charge

Experimental
mass

838.8935
842.8922
671.3163
674.5155
559.5981
562.2639

-0.2
-6.8
0.4
-0.08
2.2
1.1

4
4
5
5
6
6

3351.546
3369.555
3351.544
3367.541
3351.538
3367.536

M+4H
M+4H+O *
M+5H
M+5H+O *
M+6H
M+6H+O *

7.3
1.5
28.9
6.6
14.3
2.1

870.8833
866.8846
700.1071
696.9081
693.7091
583.5904
580.9246
578.2588

0.5
-2.9
2.6
-0.03
0.7
2.7
2.0
1.3

4
4
5
5
5
6
6
6

3479.502
3463.519
3495.49
3479.504
3463.507
3495.489
3479.497
3463.505

M+8O+4H *
M+7O+4H
M+9O+5H *
M+8O+5H *
M+7O+5H
M+9O+6H
M+8O+6H
M+7O+6H

3.2
4.9
10.8
24.0
28.3
8.1
26.9
33.9

Ion*

S/N
ratio

Table shows S/N ratios, mass accuracy, and charge state of the ions. Theoretical
Monoisotopic Mass of Nisin A (M) is 3351.5449; (H) is proton; (O) is oxygen.“*”
indicates that the peaks are a mixture of products corresponding to addition of oxygen(s)
and one water molecule.

Characterizing the Biological Properties of the Oxidized Product
Bactericidal assays, TEM, and a lipid II affinity assay were developed to
characterize the bioactive properties of oxidized nisin A. First a deferred-antagonism
assay, a qualitative assay, was done to determine the bioactivity of oxidized nisin A. The
oxidized nisin A sample produced no zones of inhibition on the plate, while the nisin A
sample gave significant clearing (data not shown). These results demonstrated that
oxidation of nisin A did have a significant effect on the bioactivity of nisin A.

71

A quantitative bioassay was done to determine the MICs of nisin A and oxidized
nisin A against a wide phylogenetic range of susceptible bacterial species: M. luteus, S.
aureus, and S. pneumoniae. These bioassays showed acomplete loss of bactericidal
activity by oxidized nisin A. The MICs of nisin A were found to be 6.2µg/mL,
31.25µg/mL, and 31.25µg/mL against M. luteus, S. aureus, and S. pneumoniae,
respectively (Table 2.2). The oxidized nisin A showed no activity against any of these
bacterial strains in the tested concentration range. Oxidized nisin A does not appear to
have an antagonistic effect on the bioactivity of nisin A. The MICs for nisin A in the
presence of an equal molar concentration of oxidized nisin A were also 6.25µg/mL,
31.25µg/mL, and 31.25µg/mL against M. luteus, S. aureus, and S. pneumoniae,
respectively.

Table 2.2
Bioassay Activity of Nisin, Gallidermin, and Their Oxidized Variants
Indicator
Strain

Activity (AU/mL)

MICs (g/mL)
Nisin A

Oxidized
Nisin A
>250

M. luteus

6.25

S. aureus

31.25

>250

S. pneumoniae

31.25

>250

Nisin A and
Oxidized Nisin A
6.25

Gallidermin

Oxidized
Gallidermin

125

0

31.25

125

0

31.25

N.D.

N.D

N.D. Not determined

There are three potential reasons for the observed loss of bioactivity: (i) oxidized
nisin A has reduced capacity for binding and inserting into bacterial membranes; (ii)
oxidation of nisin A prevents the oxidized nisin A from assembling into large complexes,
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preventing the abduction of lipid II; or (iii) oxidation of nisin A reduces its affinity for
lipid II. Based on the HPLC elution profiles, the hydrophobicity properties of nisin A and
oxidized nisin A seem to be the same. Therefore, oxidized nisin A most probably is still
as capable of interacting with the bacterial membrane as nisin A.
Initially TEM was performed to visualize pore complexes formed by mutacin
1140 on vesicle membranes. Instead unusual circular objects were observed in the
background. To further investigate these objects, mutacin 1140 in acetonitrile-water
(80:20) was applied to a carbon-coated grid for 4 minutes and stained. Large circular
objects averaging 50nm in diameter for the largest were present (Figure 2.3A). These
objects were not present in the negative control sample of acetonitrile-water (80:20). In
order to determine if this phenomenon is a trait of lantibiotics in general, the same
procedure was performed with nisin (Figure 2.3B). The results were the same. This
suggests that lateral assembly is a property that lantibiotics possess.

Figure 2.3
TEM Images of Mutacin 1140 and Nisin A Complexes.
A. TEM image of mutacin 1140 complexes. B. TEM image of nisin A complexes.
Both mutacin 1140 and nisinA (20µM) were floated on carbon coated grids for 4
minutes. The grids were then stained with 2% uranyl acetate for 30 seconds and
images were taken at a magnification of 40,000X. Both formed large circular
complexes on the grids. A black box is drawn around each of these complexes.
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To determine whether oxidation of nisin A had an effect on its ability to assemble
into large complexes, we performed the same TEM experiments using oxidized nisin A
(Figure 2.4). As observed by TEM, oxidized nisin A is also capable of assembling into
large circular complexes. These data suggested that oxidation does not affect the
mechanism for lateral assembly, so we next determined whether oxidation of nisin A had
an effect on the affinity of nisin A for lipid II.

Figure 2.4
TEM Images of Nisin A and Oxidized Nisin A Complexes
A. TEM image of nisin A complexes. B. TEM image of oxidized nisin A complexes.
Both nisin A and oxidized nisin A (20µM) were floated on carbon coated grids for 4
minutes. The grids were then stained with 2% uranyl acetate for 30 seconds and images
were taken at a magnification of 40,000X. Both formed large circular complexes on the
grids. A black box is drawn around each of these complexes.

A TLC affinity assay was developed to observe whether oxidized nisin A could
bind to lipid II. The basis for this assay is that nisin A and oxidized nisin A are stationary
on the TLC plate and thebinding of lipid II by nisin A or oxidized nisin A would
immobilize lipid II. In this assay, lipid II migrated away from the origin in the lipid II
lane and in the lanes with 3:1 and 12:1 molar ratios of oxidized nisin A to lipid II. The
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migration of lipid II away from the origin in these samples suggests that oxidized nisin A
did not bind to and prevent the migration of lipid II. Lipid II was retained at the origin in
the lanes with 3:1 and 12:1 molar ratios of nisin A to lipid II (Figure 2.5A),
demonstrating nisin A’s ability to bind and prevent the migration of lipid II. The increase
in lipid II binding was visible on the TLC plate as the molar ratios of nisin were
increased. A second plate containing nisin A and oxidized nisin A without lipid II was
used as a control to ensure that the lantibiotics did not stain with iodine (Figure 2.5B).
These results provide a direct means of observing the loss of nisin A’s affinity for lipid II
following oxidation.
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Figure 2.5
Affinity Assay of Nisin A and Oxidized Nisin A for Lipid II
A. Plate 1: Lane1. 0.068 mM lipid II, lane 2.nisin:lipid II (3:1), lane 3. nisin A:lipid II
(12:1), lane 4. oxidized nisin A:lipid II (3:1), and lane 5. oxidized nisin A:lipid II (12:1).
B. Plate 2: Lane1. 0.068mM lipid II, lane 2. 0.2mM nisin A, lane 3. 0.8mM nisin A, lane
4. 0.2mM oxidized nisin A, and lane 5. 0.8mM oxidized nisin A. Plates were visualized
by staining with iodine.

Confocal laser scanning microscopy was used to determine whether the loss of
lipid II binding could also be observed in vivo. Previously, it was reported that
fluorescein labeled vancomycin is capable of binding to lipid II, demarcating regions that
are actively undergoing cell wall formation (29). Shortly thereafter, nisin A was shown to
abduct lipid II from these physiological domains (18). Following an approach similar to
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that described in the above-mentioned references, B. megaterium cells were treated with
nisin A and the oxidized variant of nisin A to determine if there were any visible
differences in their abilities to abduct lipid II. In Figure 2.6A, as a positive control for our
fluorescein labeled vancomycin sample, B. megaterium cells were incubated for 1 min
with our vancomycin:fluorescein-labeled vancomycin probe (2µg/mL).
Green fluorescence showed areas within the bacteria that were actively
undergoing new cell wall formation. In Figure 2.6B, B. megaterium cells were incubated
with nisin A (15µg/mL) for 10 min, followed by a1 min incubation with the
vancomycin:fluorescein-labeled vancomycin probe (2µg/mL). The diminution of
fluorescence indicated no discernible localization of lipid II, demonstrating that lipid II
had been abducted by nisin A from the physiological domains. In Figure 2.6C, B.
megaterium cells were incubated for10 min with the oxidized variant of nisin A
(15µg/mL), followed by a 1 min incubation with the vancomycin:fluorescein-labeled
vancomycin probe (2µg/mL). The oxidized form of nisin A did not remove lipid II from
its physiological domains in the bacterium, supporting our assumption that oxidation of
nisin A results in a loss of lipid II binding.
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Figure 2.6
Oxidized Variant of Nisin does not Abduct Lipid II from Its Physiological Domain
Phase-contrast image, fluorescent image, and superimposed image of B. megaterium cells
after treatments. A. Cells were incubated for 1 min with the vancomycin:fluoresceinlabeled vancomycin probe (2µg/ml). B. Cells were preincubated with nisin A (15µg/ml)
for 10 min, followed by a 1 min incubation with the vancomycin:fluorescein-labeled
vancomycin probe (2µg/ml); the lack of fluorescence indicates abduction of lipid II by
nisin A. C. Cells were preincubated with the oxidized form of nisin A (15µg/ml) for 10
min, followed by a 1 min incubation with the vancomycin:fluorescein-labeled
vancomycin probe (2µg/ml). The fluorescence represents newly forming division sites,
which are indicated by the arrows.

As discussed above, the N-terminal portion of nisin A comprising lanthionine
rings A and B is considered to be the lipid II binding domain (Figure 2.1). Presumably,
oxidation of the thioether linkages of rings A and B are responsible for the observed loss
of oxidized nisin A’s affinity for lipid II. To further test this idea, we oxidized
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gallidermin, which shows sequence and structural homology to only the N-terminal
portion of nisin A (Figure 2.1). A TEM experiment was also performed on oxidized
gallidermin. The experiment also showed that oxidized gallidermin’s ability to form large
complexes was unaffected by oxidation (Figures 2.7). Due to a limited amount of
gallidermin, a deferred-antagonism assay was done to determine the effects of oxidation
on bioactivity (Table 2.2). This assay also showed a complete loss of bactericidal activity
by the oxidized variant of gallidermin. These data further support our
assumption/hypothesis that an oxidation event on lanthionine ring A and/or B would
render this group of antibiotics inactive, since gallidermin and nisin A share structural
homology only in this portion and since rings A and B are known to be the lipid II
binding domain for these antibiotics.

Figure 2.7
TEM Image of Oxidized Gallidermin
Oxidized gallidermin (20µM) were floated on a carbon coated grid for 4 minutes. The
grid was then stained with 2% uranyl acetate for 30 seconds and an image was taken at a
magnification of 40,000X. Large circular complexes were seen on the grid. A black box
is drawn around one of these complexes.
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Discussion
The findings from this study include an efficient chemical modification procedure
for generating oxidized variants of lantibiotics, bioassay experiments showing an obvious
loss of antimicrobial activity following oxidation, the fact that nisin A and gallidermin’s
inherent ability to form large circular complexes is not affected by oxidation, and, finally,
a lipid II affinity assay and in vivo fluorescence studies demonstrating that oxidation of
nisin A results in a loss of lipid II binding. These results suggest that the loss of
bioactivity of oxidized nisin A and oxidized gallidermin is attributable to an inability to
bind and sequester lipid II that would subsequently inhibit cell wall formation.
The results of this study also show that mutacin 1140 like nisin A forms circular
complexes indicative of lateral assembly.The covalent and three-dimensional structures
of mutacin 1140 were determined by nuclear magnetic resonance (NMR) and that data
showed that mutacin 1140 exists as a monomer in solution (19, 30). This was evident
since all samples had narrow line widths and did not show any changes in chemical shift
when mutacin 1140 was diluted (19). Taking all of the previous data into account, the
only plausible explanation for the large circular complexes seen by TEM is that mutacin
1140 is capable of self-assembly. This mechanism might have been activated by exposure
to the hydrophobic carbon-coated grid. The dimensions of mutacin 1140 that were
previously determined from the 3D-NMR structural analysis were estimated to be 26 x 14
Å in width and 17 Å in depth (19, 28). This suggests that each complex is roughly
composed of over 100 monomers of mutacin 1140. Since the complexes for nisin A are
similar to those seen for mutacin 1140 it can be assumed that nisin’s complexes are
composed of the same number of monomers.
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There is a considerable number of naturally occurring and newly designed
oligopeptides that have been shown to form a variety of nanostructures via self-assembly.
Some examples are neurofilaments (NFs), the most abundant cytoskeletal components in
large myelinated axons and comprised of NF-L, NF-M and NF-H (31, 32), along with
amyloid peptides such as Aβ1-40 and Aβ1-42 which both undergo self-assembly (33).
The complexes formed either allow cross-bridge formation with NF-M and NF-H as seen
for NF-L (34) or cause fibrillar deposits in Alzheimer patient’s brains as is the case for
the amyloid peptides (33). The underlying mechanisms of peptide self-assembly are
slowly being unraveled. However, it is currently recognized that the relatively weak noncovalent forces such as hydrogen bonding, hydrophobic interaction, electrostatic
interaction, and van der Waals interaction, play a crucial role in both molecular
recognition and mediation of the assembly kinetics and structures (33).
The interaction of nisin A with lipid II involves a novel lipid II binding motif that
has been characterized by NMR (17). In this three-dimensional structure of nisin A-lipid
II complex, the thioether bridges of rings A and B are in close proximity to the negatively
charged pyrophosphate group. Given the close interaction of the thioether linkages with
lipid II, it would not be surprising that altering the chemical nature of these rings would
affect nisin A’s affinity for lipid II. The addition of one and two oxygens in nisin A has
been previously described (35). The authors attributed this to oxidation of Met17 and/or
Met21 and presented NMR data supporting oxidation of only Met21. The susceptibility
of the thioether linkages in methionine residues to naturally occurring oxidation supports
the possibility for oxidation of the thioether linkages in the lanthionine bridges, since
both would be equally reactive.
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The bond between the sulfur and the oxygen in a sulfoxide differs from the double
bond that would occur between a carbon and oxygen. The S-O single bond and S=O
double bond would occur in equilibrium. The S-O single bond is electrostatic and results
in a dipole character, with the negative charge centered on the oxygen and the positive
charge on the sulfur. The negative charge on the oxygen would therefore most probably
play a more significant role in the loss of nisin A affinity for lipid II due to electrostatic
repulsive forces rather than steric hindrance. This is a reasonable argument in light of the
fact that the lanthionine thioethers are very close to the pyrophosphate moiety of lipid II.
When considering lantibiotics, nisin A is the only one that has been subjected to a
considerable amount of research concerning resistance (36-43). Very little is known
about resistance to other lantibiotics, such as gallidermin, although work has been done to
show how resistance works in the producer strain of the antibiotic (44). There are three
known resistance pathways for nisin A: (i) ABC peptide, NisFEG, transport of the
antibiotic out of the membrane to the extracellular space; (ii) sequestering of extracellular
nisin A by the lipoprotein NisI, preventing nisin A from abducting lipid II; and (iii)
changes in the cell wall that prevent nisin A’s access to lipid II. Whether the occurrence
of oxidation in vivo could be a fourth mechanism of bacterial resistance is currently
unknown but is an area our group is actively investigating.
These findings open new areas of study in which the effects of lantibiotic
oxidation need to be considered. This work supports future studies aimed at investigating
the role of oxidation of lantibiotics as a potential resistance pathway. We have also
described a nisin A variant that is still capable of self-assembly but cannot bind to lipid
II. This may be useful in future studies aimed at better understanding the functions of
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these compounds. As nisin A, and potentially other lantibiotics, move forward with
commercial applications, minimizing the oxidation of these compounds will need to be
addressed in their manufacture. Studies to determine the effect oxidation has on the
pharmacokinetics and pharmacodynamics of these compounds will also have to be done.
The thioether linkages could potentially be enzymatically oxidized by the liver during an
antibiotic treatment regimen, which could have profound effects on the pharmacokinetics
and pharmacodynamics of the antibiotic (45, 46). Our work reveals the importance of
lanthionine structure for bactericidal activity and promotes several new areas of study.
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CHAPTER III
CHEMICAL MODIFICATION OF DEHYDROBUTYRINE LEADS TO THE FIRST
EVER IN VIVO IMAGES OF GALLIDERMIN

Abstract
Gallidermin is produced by Staphylococcus gallinarium and is a type A (I)
lantibiotic. Lantibiotics are ribosomally synthesized bacteriocins that acquired their name
from the characteristic lanthionine structures they contain. Lantibiotics also contain other
unusual amino acids like 2,3-didehydroalanine (Dha) and 2,3-didehydrobutyrine (Dhb)
produced from the dehydration of serine and threonine respectively. Utilizing the Dhb at
position 14 of gallidermin, three chemical derivatives were generated: βmercaptoethanol-gallidermin (BME-gallidermin), ethanethiol-gallidermin (Ethanegallidermin), and thiolactic acid-gallidermin (Thiol-gallidermin).
Reverse-phase HPLC was used to purify each sample. MALDI data showed the
addition of one to two molecules of each thiol-compound. MIC data showed that all
chemical derivatives were bioactive in the nanomolar concentration range. A deferred
antagonist assay showed that the zone of inhibition for the chemical derivatives were 4066% smaller than the native compound. A TLC lipid II binding assay showed that the
chemical derivatives were still able to bind to lipid II. Fluorescently labeled gallidermin
was produced utilizing the same chemistry used to generate the thiol chemical
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derivatives. Confocal microscopy results showed clustering of lipid II by gallidermin
similarly to what was reported for nisin. These were the first ever in vivo images of
gallidermin and opens doors for further studies.

Introduction
Mutacin 1140 is a bacteriocin produced by Streptococcus mutans JH 1140. It
belongs to a special group of antibiotics known as lantibiotics. Lantibiotics undergo posttranslational modifications that result in the formation of lanthionine or βmethyllanthionine rings as well as other unusual amino acids such as 2, 3didehydroalanine (Dha), 2, 3-didehydrobutyrine (Dhb), and S-amino vinyl-D-cysteine
(AviCys) (1). The emergence of multi-drug resistant bacteria have caused urgency for the
discovery/development of novel or modified antibiotics to replace those that are currently
failing. Lantibiotics like mutacin1140 are receiving a considerable amount of attention
because of their broad spectrum of activity, high potency, low immunogenicity, and good
structural stability. More importantly, there have been no reports of genetically stable
resistant variants of sensitive strains.
Nisin is a lantibiotic produced by Lactococcus lactis and has been used in the
food industry for over 50 years. The rings A and B, known as the lipid II binding domain,
of nisin and mutacin 1140 are very similar. This similarity led to the assumption that
mutacin 1140 could induce pores similarly to nisin. However, this assumption was
disproved asit was shown that mutacin 1140 did not induce pores (2) but in fact, induces
clustering of lipid II into large patches in both membrane vesicles and in vivo membranes
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(1). In order to have this clustering effect it is assumed that there must be some type of
lateral assembly mechanism involved; a single monomer of mutacin 1140 or nisin could
not be responsible for the abduction of lipid II or pore formation using lipid II as a
docking molecule. This assumption is further supported by the fact that through pyrene
fluorescence and circular dichroism it was determined that the nisin-lipid II pore consists
of a minimum of 8 nisin and 4 lipid II molecules for a 2:1 ratio (3).
Chemical modification is often done to improve an antibiotic’s therapeutic
potential either by increasing its antimicrobial activity or reducing/eliminating any
adverse side effects. To aid in the fight against vancomycin resistant pathogens, various
chemical modifications have been made to glycopeptides like vancomycin, teicoplanin,
and ristocetin (4, 5). In one such study it was found that the methyl ether derivatives of
vancomycin, teicoplanin, and ristocetinaglycon all exhibited increased bactericidal
activity against VanB resistant strains (5). The derivatives for ristocetinaglycon did not
cause platelet agglutination like the parent peptide, thus overcoming the side effect that
caused the cessation of clinical use of ristocetin (5). Another study showed that a
hydrophobic substitution to the vancosamine nitrogen of vancomycin was active against
VanA resistant strains.
Using structural data from several experiments it was determined that the Dha5
residue of mutacin 1140 protrudes out from ring A (3) and that the side chains of the
Dha/Dhb residues are free for manipulation in the nisin-lipid II interaction (6). Nisin
mutants that had their Dhb2 replaced with Val or Ala or Dha5 replaced with Dhb showed
similar biological activity as the wild-type (7, 8). Gallidermin, a lantibiotic produced by
Staphylococcus gallinarium, belongs to the same subgroup as mutacin 1140 and has
91

similar rings A and B (Figure 3.1). Gallidermin mutants with replacement of Dhb14 with
Dha also showed similar activity as the wild-type (9) suggesting that the Dha/Dhb
residues are amendable to modifications. The hypothesis is that modifications of the
Dha/Dhb residues may make it possible to enhance bactericidal activity and/or allow
labeling of lantibiotics that cannot be labeled using standard practices.
To investigate modifying Dhb and/or Dha residues gallidermin was used.
Gallidermin has only one dehydrated residue to modify compared to two dehydrated
residues found in mutacin 1140 (Figure 3.1). This eliminates the confusion of whether the
effects seen are from a combination of Dhb/Dha modification. To determine the
amenability of the Dhb residue, three thiol-containing compounds were used, βmercaptoethanol (polar), thiolactic acid (negatively charged), and ethanthiol (nonpolar)
(Table 3.1). These particular thiol-compounds were used to assess the effect of different
functional groups on bactericidal activity. Using this same chemistry it was possible to
label gallidermin and provide the first ever images of activity in vivo for this subgroup of
lantibiotics.
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Figure 3.1
Covalent Structure of Gallidermin and Mutacin 1140
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Table 3.1
Commercially Available Thiol Chemicals

Experimental Design

Antimicrobial Agents
Nisin was extracted from Streptococcus lactis, 2.5% (Sigma Chemicals). Five
hundred mg of nisin was dissolved in 10mL of 35% ACN-0.1%TFA and sonicated for 15
minutes (4710-Ultrasonic Homogenizer, Cole-Palmer Instrument Co.). The solution was
then centrifuged (Sorval RC-5B refrigerated Superspeed Centrifuge with GSA rotor; Du
Pont Instruments) at 10,000 rpms for 10 minutes to remove any insoluble material.
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Extracted nisin was purified by HPLC. Gallidermin was purchased from Alexis
Biochemicals and diluted in distilled water (d-H2O) to a final concentration of 10mg/mL.
Mutacin 1140 was given as a gift from Oragenics.

Chemical Modifications
Using the gallidermin stock solution (10mg/mL), 10µL was added to three 1.8mL
eppendorf tubes and dried down in a speedvac with no heat (Savant DNA 120
SpeedvacConcentrator, Thermo) until dry. 120µL of 100mM TrispH7.5 was added to two
tubes. Then 30µL of either β-mercaptoethanol (≥99%, Sigma Aldrich) or ethanethiol
(≥99, Sigma Aldrich) was added. The reaction for thiolactic acid (≥95%, Sigma Aldrich)
was performed in 120µL of 500mM Tris and the pH of the acid was adjusted to 5.5 with
6N NaOH before 30µL was added. All tubes were than incubated at 55°C for 2-3 days.
After incubation, 0.1%TFA was added to each tube to a final volume of 1mL before
purification by RP-HPLC. The resulting derivatives were named BME-gallidermin,
Ethane-gallidermin, Thiol-gallidermin, and Gallidermin:Thiol-gallidermin respectively.
Gallidermin was labeled with 5-((2-(and-3)-S-(acetylmercapto)succinoyl)amino)fluorescein (SAMSA flu, A-685). To activate SAMSA, it was dissolved in 500µL of
0.1M NaOH and incubated at room temperature for 25 minutes. The solution was than
neutralized by adding 7µL of 6M HCl and stored at -20°C. To label gallidermin, 100µg
of gallidermin was dried and resupended in 100µL of Tris pH 7.5. 30µL of SAMSA was
added and the sample was incubated at 55°C for 2-3 days. Distilled water with 0.1%TFA
was added to a final volume of 1mL and RP-HPLC was performed.
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Nisin and vancomycin were labeled with 5-(aminoacetamido)-fluorescein (AAAflu) as follows. 150µg of each antibiotic was dried in a speedvac with no heat (Savant
DNA 120 Speedvac Concentrator, Thermo) then resuspended in 90μL
dimethylformamide (DMF) and transferred to glass bottles. To each bottle 4.3µLN-(3dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC - 15mM), 2µL1hydroxy-7-azabenzotriazole (HOAt - 30mM), and 2µL AAA-flu were added. Samples
were parafilmed and wrapped in foil then allowed to incubate overnight at room
temperature. The labeled nisin and vancomycin were purified from the reaction mixture,
after evaporation of the DMF, using RP-HPLC.

Reverse Phase-High Pressure Liquid Chromatography (RP-HPLC)
HPLC was used in the final purification step of all lantibiotics used in this study.
The Bio-Rad BioLogic Duo Flow with Quad Tec UV-Vis Detector system was used. The
two buffers used to establish an ACN gradient were solvent A (99.9% ACN-0.1% TFA)
and solvent B (99.9% d-H2O-0.1% TFA). 90% solvent B was run on the column (Higgins
Analytical Clipeus C18, P/N CS-2546-C185) for 5 minutes at the constant flow rate of
1mL/min to stabilize the baseline. After the isocratic flow, 1mL of prepared sample was
loaded onto the column. This was immediately followed by a baseline zeroing and linear
gradient establishment. Solvent B was decreased from 90% to 20% over a 30 minute
period. Following the gradient flow was an isocratic flow of 90% solvent B for 5
minutes. MALDI-TOF (BrulerABI 4700 Proteomics Analyzer) was used to verify all
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suspected HPLC fractions using anα-cyano-4-hydroxycinnamic acid matrix. Gallidermin
(1µg/µL) with a mass of 2165 Da was used as the mass standard for MALDI.

RP-HPLC 2
For HPLC fractions that were determined to be mixtures of unlabeled and labeled
gallidermin, a second round of HPLC was performed. The same system and solvents
were used as described previously. 90% solvent B was run through a C18 mini-prep
column (Higgins Analytical Clipeus C18, P/NCS-2546-C185) for 5 minutes at the
constant flow rate of 1mL/min to stabilize the baseline. After the isocratic flow, 1mL of
prepared sample was loaded onto the column. This was immediately followed by a
baseline zeroing and linear gradient establishment. Solvent B was decreased from 90% to
60% over a 15 minute period. This was followed by another linear gradient that
decreased solvent B from 60% to 50% over a 15 minute period. Following the gradient
flow was an isocratic flow of 90% solvent B for 5 minutes. MALDI-TOF was used to
verify all suspected HPLC fractions using anα-cyano-4-hydroxycinnamic acid matrix.

Bioactivity Assay
All media were purchased from Difco Laboratory. A quantitative method was
used to determine the MIC of gallidermin and its chemical derivatives. Micrococcus
luteus ATCC 272 was grown in a 50mL tube containing 20mL of Todd Hewitt-yeast
extract (THyex) broth (30g/L Todd Hewitt Broth [THB] and 3g/L Yeast extract) to an
OD600 of 0.6 and then diluted 100 fold. A 50mL tube containing 10mL of top agar
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(30g/L THB and 7.5g/L Nutrient agar) was inoculated with 400µL of the bacterial strain.
A 48-well plate was used to perform a 2-fold serial dilution of each antibiotic, starting
concentration of 2µg/mL in duplicates using d-H2O with 0.1% acetic acid as the diluting
solvent. 200µL of the top agar/cell suspension was added to each well and allowed to
solidify at room temperature. The plates were then covered and incubated at 37°C
overnight. The MIC was determined as the lowest concentration showing inhibition of
visual growth.
A deferred-antagonism assay was also used for comparing the activities of
gallidermin and its chemical derivatives. M. luteus was grown to an OD600 between 0.4
and 0.8 and diluted to an OD600 of 0.2. Then, 400µL of these cells was added to 10mL
of top agar. All 10mL of melted top agar containing the standardized suspension was
added to a 150 X 15mm petri dish (Fisher Scientific, Pittsburg, PA) containing
approximately 25mL of THyex agar (30 g/liter THB, 3 g/liter yeast extract, and 15 g/liter
of nutrient agar). Gallidermin and its derivatives (10µg/mL) were made in 100µL of
acidified distilled water. Once the top agar on the petri dish solidified, 5 µL of each
sample (0.5µg/µL) was stabbed in triplicate on the plate. The plates were allowed to dry
before being inverted and placed in a candlejar overnight at 37°C. Zone diameters were
measured in mm and percentages were expressed as compared to unmodified gallidermin.

Thin Layer Chromatography
A 50mL stock of Solution A (butanol, acetic acid, water, and pyridine [15:3:12:10
v/v/v/v]) was made for this experiment. In glass vials gallidermin, BME-gallidermin, and
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Thiol-gallidermin were added in a 12:1 ratio with respect to lipid II. These samples were
allowed to air dry and 10µL of reaction mixture (8µL of Solution A/2µL lipid II for those
samples to be run with lipid II or 10µL of Solution A for those to be run without) was
added. This was allowed to incubate at room temperature for two hours. Samples were
then spotted on a TLC plate (5 X 10cm silica gel 60 F254, Merck) and air dried. The plate
was inserted into its own chamber consisting of 10-15mL of Solution A and allowed to
run until the solvent front was roughly 2-4cm from the top. The plate was then removed
and allowed to air dry once again before being stained in an iodine chamber. The picture
was taken using a UVP MultiDoc-It Digital Imaging System.

Confocal Laser Scanning Microscopy
Bacillus megaterium de Bary (ATCC 14581) was grown at 37°C in THyex broth
(30 g/liter THB and 3 g/liter yeast extract) overnight. 20mL of fresh THyex broth was
inoculated with 2mL of the overnight culture and allowed to reach an OD600 of 0.6-0.8.
Gallidermin:SAMSA-labeled gallidermin (50:50) at a final concentration of 8μg/mL was
added to 100µL of cell suspension and incubated for 5 min at room temperature.
Vancomycin:fluorescein-labeled vancomycin (50:50) and nisin:fluorescein-labeled nisin
(50:50) was added to the same amount of cells at the same concentration and incubated
for 1 minute. The cells were washed three times with an equal volume of phosphatebuffered saline, fixed with 1.6% formaldehyde for 1 h on ice, and resuspended in
phosphate-buffered saline. The cell suspensions were applied to a glass slide and mixed
with an equal volume of 2% low-melting-point agarose to immobilize the sample. The
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immobilized B. megaterium bacteria were analyzed on a Zeiss Axiovert 200 Minverted
research microscope with a Plan-Apochromat 100×/1.40 oil objective. The labeled
antibiotics appear green upon excitation by an argon laser (488 nm). Phase-contrast
optics was used for detection of bacteria. LSM 5 image browser software was used for
analysis of the images and control of the microscope.

Results

Dhb Modification and Purification
Three tubes each containing 100µg of gallidermin were modified with 30µL of βmercaptoethanol, ethanethiol, or thiolactic acid in a buffered solution. The resultant
chemical derivatives were then purified by RP-HPLC. The elutions were 56% solvent B
for BME-gallidermin (Figure 3.2A) and 54% for Ethane-gallidermin (Figure 3.2B).
Multiple peaks eluted at 51, 54, and 55% solvent B for Thiol-gallidermin (Figure
3.2C).The Thiol-gallidermin fractions that eluted at 51 and 54% were pooled and called
Thiol-gallidermin (Figure 3.2C). The other peak that eluted at 55% solvent B was called
Gallidermin:Thiol-gallidermin (Figure 3.2C). These fractions, along with the fraction
collected at 54% solvent B for ethanethiol, were shown to be mixtures of labeled and
unlabeled gallidermin. Samples underwent a second round of RP-HPLC to separate out
the unlabeled material. Ethane-gallidermin eluted at 59% solvent B (Figure 3.2D) while
both Thiol-gallidermin and Gallidermin:Thiol-gallidermin eluted at 58% (Figure 3.2E
and F).
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Figure 3.2
HPLC Chromatogram of Gallidermin’s Chemical Derivatives
Panels A-C are chromatograms from the first round of HPLC. Panels D-F are
chromatograms from the second round of HPLC that was performed to obtain better
separation of labeled and unlabeled material.

Using gallidermin (10µg/µL) as a standard (Figure 3.3A), MALDI was performed
for the thiol-compound derivatives. Suspected HPLC fractions were dried down and
resuspended in 10µL of 50% acetonitrile. A 50:50 mix of each sample and α-cyano-4hydroxycinnamic acid were spotted onto the sample plate. The data showed a mixture of
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single and double addition of β-mercaptoethanol for BME-gallidermin (Figure 3.3B). For
the ethanthiol reaction there was a single addition with some unlabeled gallidermin
present (Figure 3.3C). Thiol-gallidermin contained a mixture mostly composed of a
single addition of thiolactic acid with a small amount of both double and unlabeled
gallidermin (Figure 3.3D). Gallidermin:Thiol-gallidermin contained a mixture that is
approximately 50:50 single addition and unlabeled gallidermin with a small amount of
double labeled material (Figure 3.3E). The MALDI data suggests that when collecting
HPLC a portion of unmodified gallidermin and thiol-gallidermin was collected for the
Gallidermin:Thiol-gallidermin sample. The unlabeled gallidermin could not be separated
from the ethanethiol and thiolactic acid reactions even with a second round of HPLC.

.
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Figure 3.3
MALDI-TOF Spectra of Gallidermin and Its Chemical Derivatives
HPLC fractions were dried and resuspended in 10µL of 50% ACN. Equal volumes of
each fraction and α-cyano-4-hydroxycinnamic acid were mixed and spotted onto the
MALDI plate. Panel A. Gallidermin (1µg/mL), B. BME-gallidermin, C. Ethanegallidermin, D. Thiol-gallidermin, and E. Gallidermin:Thiol-gallidermin
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Bioactivity of Gallidermin and Its Chemical Derivatives
A quantitative bioassay was done to determine the MIC of gallidermin and its
chemical derivatives against the susceptible bacterial species Micrococcus luteus ATCC
272 (Table 3.2). The bioassay showed a great reduction in the bactericidal activity of the
chemical derivatives. The MIC against M. luteus for BME-gallidermin, Ethanegallidermin,Thiol-gallidermin, and Gallidermin:Thiol-gallidermin were 0.25, 0.5, 1, and
0.125µg/mL respectively. Although there was a loss of activity (thus disproving the first
portion of the proposed hypothesis) for the chemical derivatives, the compounds are still
very potent antibiotics with MICs in the nanomolar range. Also the MICs obtained for the
derivatives are similar to or better than those seen for wild-type gallidermin against M.
luteus ATCC 9341 and 15957 (10).

Table 3.2
MIC of Gallidermin and Its Chemical Derivatives
Lantibiotic

MIC (µg/mL)

Gallidermin

0.015625

BME-Gallidermin

0.25

Ethane-Gallidermin

0.5

Thiol-Gallidermin

1

Gallidermin:Thiol-Gallidermin

0.125

A 2 fold serial dilution of each sample was performed in duplicate using M. luteus at
OD600 0.6. 400µL of diluted cell was added to 10mL of molten top agar (40°C). 200µL
of the suspension was added to each well and allowed to solidify. Plates were incubated
overnight at 37°C. MIC was determined as the last well showing inhibition of growth.
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Samples were also subjected to a deferred antagonist assay using M. luteus ATCC
272 as the indicator strain. Exactly 5µL of each sample (10µg/mL) was stabbed in
triplicate on plates containing top agar with the standardized bacterial suspension (Figure
3.4). Plates were inverted and incubated at 37°C in a candlejar overnight. An average of
zone size was calculated and compared to the standard. BME-gallidermin and
Gallidermin:Thiol-gallidermin had zones that were 60% of the size of the standard.
Thiol-gallidermin and Ethane-gallidermin both had zones that were 33.33% that of the
standard. The results of the bioassay show an 8 fold decrease in bioactivity for the
chemical derivatives; however, there was a loss of only 40-66% in zone diameter (Table
3.3).

Figure 3.4
Deferred Antagonist Plate Assay
M. luteus was grown to an OD600 0.6 and diluted to 0.2. 400µL of diluted cells was
added to 10mL molten top agar (40°C) and poured into a large THYex plate. Once
solidified, 5µL of each sample (0.5µg/µL) was stabbed in triplicate and allowed to dry
before being placed in a candlejar overnight at 37°C.

105

Table 3.3
Zone of Inhibition Diameter for Gallidermin and Its Chemical Derivatives
Lantibiotic
Gallidermin

Zone Diameter
(mm)
15

% of Wild-type

BME-Gallidermin

9

60

Ethane-Gallidermin

5

33.33

Thiol-Gallidermin

5

33.33

100

Gallidermin:Thiol9
60
Gallidermin
Zone diameter is expressed as the average (n=3). The percent wild-type is in reference to
the ratio of chemical derivative to wild-type average zone size.

Inhibition of Lipid II Migration as Seen by TLC
Sample concentrations were matched by taking absorbance readings at OD280 on
a spectrophotometer (Nanodrop ND-1000 Spectrophotometer, Thermo Scientific) with
gallidermin (1µg/µL) serving as the standard. Each sample was combined with lipid II in
a 12:1 ratio. Using a slightly modified version of a previously described protocol for TLC
of lipid II with lantibiotics (11) it was possible to determine if chemically modified
gallidermin was capable of inhibiting the migration of lipid II. Due to the limited amount
of chemical derivatives available, only BME-gallidermin and Thiol-gallidermin were
used in this assay. Similarly to gallidermin (Figure 3.5, lane 2) both chemical derivatives
were able to hold lipid II at the origin point (Figure 3.5, lanes 2-3) as was previously
reported for nisin (11). These results suggest that the lipid II binding properties for these
chemical derivatives are still intact. Samples without lipid II were used as controls to
ensure that the lantibiotics did not stain with iodine (Figure 3.5, lanes 5-6). Lipid II
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served as a positive control to show that it does migrate with the solvent front if not
bound (Figure 3.5, lane 1).

Figure 3.5
TLC Assay for Lipid II Binding
Samples were incubated with and without lipid II in a 12:1 ratio then spotted on a TLC
plate to determine if lipid II binding is affected. 1. lipid II, 2. gallidermin with lipid II, 3.
BME-gallidermin with lipid II, 4. Thiol-gallidermin with lipid II, 5.gallidermin, 6. BMEgallidermin, and 7. Thiol-gallidermin.

SAMSA Labeling of Gallidermin and Its in vivo Activity
Since the addition of various thiol containing compounds did not inhibit the
antibacterial activity of gallidermin, SAMSA (a thiol-containing fluorescein) was used to
fluorescently label gallidermin. Under normal circumstances gallidermin would not be
able to be labeled with the conventional fluorescent dyes as it lacks a free C-terminal that
is present in nisin (Figure 3.1). Activated SAMSA and 150µg of gallidermin were
incubated together in a buffered solution. During the purification process by RP-HPLC
several peaks were collected and checked for bioactivity (Figure 3.6). MALDI confirmed
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the addition of SAMSA for the peak that eluted at 54% solvent B (Figure 3.6). . B.
megaterium cells were treated with gallidermin:SAMSA-gallidermin (50:50) as well as
nisin:fluorescein-labeled nisin and vancomycin:flourescein-labeled vancomycin (50:50).
The images of vancomycin show localization of lipid II at the septum of newly dividing
bacteria. However, for nisin lipid II is no longer at the septum but disbursed in clusters
throughout the cell. A similar pattern of distribution was present for cells treated with
gallidermin as was seen with nisin (Figure 3.7). These are the first ever images of
gallidermin in action in vivo. This data also supports the hypothesis that labeling would
be possible.

Figure 3.6
Deferred Antagonist Assay of SAMSA:Gallidermin HPLC Fractions
M. luteus was grown to an OD600 0.6 and diluted to 0.2. 400µL of diluted cells was
added to 10mL molten top agar (40°C) and poured into a large THYex plate. Once
solidified, 5µL of each HPLC fraction was stabbed and allowed to dry before being
placed in a candlejar overnight at 37°C. The arrow indicates the fraction that was
confirmed to be SAMSA:Gallidermin by MALDI.
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Figure 3.7
Gallidermin causes Clustering of Lipid II Similarly to Nisin
B. megaterium cells were incubated with each fluorescently labeled antibiotic for 1-5min.
Cells were then washed and fixed with 1.6% formaldehyde on ice for 1 hr. Cells were
washed and immobilized on a glass slide with 2% low melt agarose. Arrows indicate the
newly forming division sites. Images were taken at 100X magnification.

Discussion
The results of this study revealed an efficient method of utilizing the dehydro
amino acids found in lantibiotics for labeling and visualization in vivo, for those
lantibiotics that are not able to be fluorescently labeled by conventional means. This is
particularly useful for fluorescently labeling members of the epidermin group, including
gallidermin and mutacin 1140, as they lack a free C-terminal that is often used for
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labeling other lantibiotics like nisin. However, the method needs to be optimized to
ensure complete labeling of the entire compound used and prevent extra additions.
Dha/Dhb residues are special residues as they have a planar shape and rigidify
peptide backbones. They are highly reactive, which allows for site-specific ligation of
peptides with thiol-containing molecules. Dehydroalanine containing peptides have been
shown to be capable of being coupled to added nucleophiles such as thiosaccharides, 2dimethylaminoethanethiol, and N-acetylcysteamine (12) exemplifying the potential of
dehydro residues to be used for site-specific coupling.
In this study it was shown that addition of a thiol compound to the Dhb residue of
gallidermin did not prevent the modified gallidermin from maintaining a nanomolar MIC
against M. luteus and binding to lipid II. Even though lipid II binding is still possible for
the chemical derivatives, a higher concentration of the modified antibiotic is needed to
achieve the same binding that can be seen at a lower concentration for the parent
antibiotic (data not shown). The premise is that lipid II binding is somehow altered but
not inhibited by the addition of the thiol-compounds. The vast difference in MIC obtained
in this study for the derivatives supports this theory.
The extra addition of the β-mercaptoethanol and thiolactic acid, as indicated by
MALDI, might explain why there was a decrease in bioactivity for these derivatives. The
additional thiol-compounds may have opened a lanthionine ring and thus altered the
bioactivity. Previous work supports this notion as it was discovered that opening of the
lanthionine rings results in the loss of bactericidal activity (13). Also the reduction in
charge that would occur from the addition of thiolactic acid could also play a role in the
decrease in bioactivity seen for Thiol-gallidermin. This change in charge would alter the
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antibiotic interaction with the negatively charged cell membrane and possibly its
interaction with lipid II. The ethanethiol derivative had only a single addition noted from
the MALDI data, and the decrease in bactericidal activity seen could be due to an
increase in hydrophobicity which would also alter the antibiotic interaction with the cell
membrane. These theories are supported by experiments that showed that a change in
charge of nisin Z C-terminus led to a 3-5 fold reduction in antibacterial activity (14).
It has been well documented that nisin binds to lipid II during both pore formation
and lipid II abduction (6, 8, 15, 16). In vitro vesicle experiments showed clustering of
lipid II for both nisin and mutacin 1140 (1). Utilizing the Dhb residue of gallidermin to
attach the fluorescent tag SAMSA, it was possibly to visualize galliderminin vivo.
Gallidermin caused clustering of lipid II similar to reports for nisin and mutacin 1140 (1).
The images obtained from this study were the first ever in vivo images of any member of
the epidermin group.
The findings from this study open a new era of research utilizing dehydro amino
acids found in lantibiotics can be used to make modifications that could possibly increase
bioactivity, solubility, or stability of the targeted lantibiotic. Lantibiotics like mutacin
1140 and epidermin can be used to determine the interaction between them and lipid II. A
drawback of lantibiotics is that they are easily degraded by digestive proteases. Thus, as
lantibiotics move into commercialization, methods will need to be developed to allow for
a better route of delivery. Using the data and methods outlined in this study it will be
possible to easily chemically modify them to accomplish that task.
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CHAPTER IV
SITE DIRECTED MUTAGENESIS OF MUTACIN 1140 AND ITS EFFECT ON
BACTERICIDAL ACTIVITY

Abstract
Mutacin 1140 is produced by Streptococcus mutans JH1140. It belongs to a
special group of antibiotics called lantibiotics. These antibiotics contain several unusual
amino acids such as 2,3-didehydroalanine (Dha), 2,3-didehydrobutyrine (Dhb), and Samino vinyl-D-cysteine (AviCys). They also contain lanthionine and/or βmethyllanthionine rings thus the name lantibiotics. Utilizing genetic manipulation
through two-step PCR, several mutants of mutacin 1140 were generated. A zone of
inhibition assay was performed and it showed that several mutants, Trp4Ala, Dha5Ala,
and Arg13Asp, had increased bioactivity when compared to wild-type. Trp4insAla and
ΔTrp4 (delete Trp4) had bioactivity that was not significantly different from wild-type
while the Alas7insAla mutant showed decreased bioactivity. From this study it was
determined that ring A is amendable to modification with the distance between rings A
and B being essential for maintaining bioactivity.
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Introduction
The occurrence of multi-drug resistant bacteria has created a great need for the
development of new antibiotics. Mutacin 1140 is a post-translationally modified
bacteriocin produced by Streptococcus mutansJH1140. It belongs to a special class of
antibiotics known as lantibiotics. Lantibiotics are aspecial group of antibiotics that
acquired their name because of the characteristic lanthionine rings that are present.
Lantibiotics are also known to have various unusual amino acids such as 2, 3didehydroalanine (Dha), 2, 3-didehydrobutyrine (Dhb), S-amino vinyl-D-cysteine
(AviCys), 2-oxopropionyl, 2-oxobutyryl, and hydroxypropionyl (1). Mutacin 1140 rings
A and B, the lipid II binding domain, is similar to nisin, a well-known lantibiotic
produced by Lactococcus lactis that has been used in the food industry for over 50 years.
It was discovered that both nisin and mutacin 1140 abducts lipid II from the site of new
cell wall synthesis ultimately causing cell death (2).
The potential for mutacin 1140 to serve as a new line of defense against multidrug resistant pathogens is demonstrated in a preclinical study in which it was tested
against a wide array of gram-positive and gram-negative bacteria, as well as yeast. The
study concluded that mutacin 1140 is bactericidal against S. pneumonia and multi-drug
resistant S. aureus, bacteriostatic against vancomycin-resistant Enterococcus faecium
(VREF), and had no activity against gram-negative bacteria or yeast (3). The study also
showed that mutacin 1140’s time-kill profiles for selected pathogens were consistent with
that of vancomycin, the antibiotic of last resort (3). The failure to find spontaneous
mutants resistant to mutacin 1140 is another trait that generates interests and may be, in
part, a reflection of the three dimensional structure of mutacin 1140.
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Work performed by Smith et. al. using the membrane mimetic solvent
acetonitrile: water (80:20) showed that mutacin 1140 has an overall horseshoe-like shape
kinked at the “hinge region” between rings B and C(4).This shape is the result of a turnlike motif in the “hinge region” that folds the N-terminal rings AB (the lipid II binding
domain) towards the C terminal overlapped rings CD (4). Interestingly, the flexibility of
the “hinge region” is believed to be important in promoting lateral assembly of mutacin
1140. The Ψ angle of Trp4 and Φ angle of Dha5 in ring A help contribute to its flexibility
(4). Also it was determined that the Ψ bond of SAla7(a residue that is not confined by the
thioether ring) freely rotates 360º allowing ring A to spin freely with respect to ring B(4).
This flexibility is thought to be important in orientating rings A and B during lipid II
binding. The “hinge region” also contains a potentially protease susceptible arginine at
residue 13 that appears to be protected. Evidence supporting this notion is reflected in
the relative difficulty of inactivating mutacin 1140 by trypsin or pronase treatment (5,
6).Considering the possible importance of the residues aforementioned, mutants were
generated to determine the effect of altering these residues and/or regions. The hypothesis
for this study is that mutagenesis of these residues will lead to altered bioactivity. The
mutants generated are Trp4Ala, Trp4insAla, ΔTrp4, Dha5Ala, Alas7insAla, and
Arg13Asp (Figure 4.1)
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Figure 4.1
Schematic of Proposed Mutations to Mutacin 1140
Abbreviations and symbols: ins = inserted and Δ = deleted.

Experimental Design

Mutagenesis of Mutacin 1140
The Streptococcus mutans genome database
(http://www.genome.ou.edu/smutans.html) and Lan gene cluster, GenBank/EMBL
accession number (AF051560), was used to design primers for the mutagenesis and
sequencing work. This ORF plus 500 base pairs (bp) of 5’ and 3’ flanking DNA was
amplified by two-step PCR using compatible primers. Reagents and media were
purchased from Fisher Scientific, enzymes were purchased from New England BioLabs,
and primers were purchased from Integrated DNA Technologies (IDT) unless otherwise
stated.
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Polymerase Chain Reaction (PCR)
Mutations were introduced into mutacin 1140 propeptide region using the p190
plasmid as a template by two-step PCR. Primers used to produce the mutants are found in
Table 4.1. PCRs were performed using Taq polymerase in a final volume of 50µL
containing 0.4 µmol of each primer,50ng of template DNA, 0.016mMdNTP, and 1 unit
of DNA polymerase in 1X polymerase buffer. Amplification conditions for each
fragment were as follows: preheat at 95°C for 1 min, followed by 27 cycles incubation
with denaturation (95°C) for30 sec, annealing (56°C) for 30 sec and extension (72°C) for
2 min followed by a final extension (72°C) for 10min.Both fragments were combined
50:50 and amplified using the two outside primers SRWlanA_1 and SRWlanA_2 under
the same amplification conditions as mentioned above.
The final PCR product was ligated into a TOPO-TA vector (Invitrogen, Carlsbad,
CA) following kit directions and transformed into DH5α-T1®cells (Invitrogen) using
standard methods and spread on LB plates containing 50µg/mL of ampicillin and 40µL
of X-gal (40mg/mL). Blue-white screening was utilized to identify colonies containing
the insert. Plasmid DNA from each colony was purified using a PureYield Plasmid
Miniprep System (Promega, Madison, WI) according to the manufacturer’s instructions.
Purified plasmid was subjected to restriction digest using EcoRI and examined by
agarose gel electrophoresis to identify those that have a cloned insert of proper size
(~1100bp). Plasmids containing the proper sized insert were sequenced using M13
Forward (-20) primer, 5´-GTAAAACGACGGCCAG-3´, to confirm the proper codon
insertion, deletion, or replacement.
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Recombination
Restriction digest was performed on purified plasmid from colonies harboring a
confirmed mutation. The insert were separated from the TOPO plasmid by
electrophoresis, excised from the gel, and purified using a Qiagen Gel Extraction Kit
(Qiagen, Valencia, CA). The purified insert was then ligated into the S. mutans suicide
vector pVA891 in a 3:1 insert:vector ratio using T4 DNA ligase at 16°C overnight. The
resultant plasmid was then transformed into DH5α cells using a standard method and
spread on LB plates containing 300µg/mL of erythromycin. Conformation of proper
insert size and sequence was performed as previously mentioned.
Mutants in pVA891 were transformed into S. mutans ATCC 55676 as follows: S.
mutans was grown overnight then diluted 1:15 in fresh THyex broth (30 g/liter THB, 3
g/liter yeast extract), 200µL of diluted cells were added to a 96 well plate and incubated
at 37°C for 2 hours. Two microliters of competence stimulating peptide (CSP, 0.1µg/mL)
was added, and plates were incubated for an additional 6 hours. Fifty microliters of cells
were then plated onto pre-warmed THyex agar plates (30 g/liter THB, 3g/liter yeast
extract, and 15g/liter of nutrient agar) containing 300µg/mL of erythromycin and
incubated at 37°C for 48 hours. Genomic DNA was extracted from clones that arose
utilizing a standard chloroform/phenol extraction method and that DNA was used as
template in a PCR that used SRWlanA_1 and SRWlanA_2 to assure the clones contained
the mutA gene.
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Confirming Genetic Identity of Mutant Constructs
Mutants were obtained by spontaneous resolution of the heterodiploid state as
follows: several confirmed heterodiploids were grown overnight in 20mL THyex broth
that did not contain erythromycin, this process was repeated using the previous overnight
culture as the inoculum (1:20 dilution into fresh media), the culture was then diluted
100,000 fold and spread onto large THyex agar plates and incubated at 37°C for 48
hours. Resultant colonies were replica patched onto medium with and without
erythromycin to identify reversion recombinants with a deleted pVA891 plasmid that
contains the erythromycin resistance gene and either the wild-type or mutated mutA gene.
Erythromycin sensitive colonies that were identified from the replica plating technique
were re-tested on medium with and without erythromycin. The erythromycin sensitive
clones were then subjected to genomic extraction and PCR as mentioned previously. The
amplicon generated was sequenced to confirm directly the presence of the engineered
mutA mutants.

Bioactivity Assay
A deferred-antagonism assay was used for comparing the bactericidal activity of
the mutants to wild-type S. mutans ATCC 55676. Mutants and wild-type S. mutans were
grown to an OD600 of 0.8 then diluted to 0.2. Two microliters of cell suspension was
spotted onto a large petri dish (150 X 15mm) in triplicate and allowed to dry. Plates were
then inverted and incubated overnight at 37°C. The following day plates were placed in a
50°C oven for thirty minutes to heat kill bacteria. M. luteus ATCC 272 was grown to an
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OD600 between 0.4 and 0.8 and diluted to an OD600 of 0.2. Then, 400µL of these cells
was added to 10mL of molten top agar (42°C) (30g/L THB and 7.5g/L nutrient agar). All
10 milliliters of top agar containing the standardized suspension was added to each plate
containing approximately 50mL of THyex agar. The plates were allowed to solidify
before being inverted and placed in a candlejar overnight at 37°C. Percentages were
ascertained by taking the ratio of zone diameter of the sample to the control (ATCC) for
each sample. The resultant data was averaged and standard deviation and p-values were
calculated.

Results

Mutant Construction
Utilizing a two-step PCR method, several mutants of mutacin 1140 was generated
(Figure 4.1). The first steps involved in generation the proposed mutations used the
outside primers with the appropriate inner primers (i.e. SRWlanA_1/Trp4Ala_2 and
SRWlanA_2/Trp4Ala_1) (Table 4.1) to produce two fragments (Figure 4.2, Step1). The
two fragments were then evenly mixed and underwent a second round of PCR using the
two outside primers, SRWlanA_1 and SRWlanA_2, to yield the final amplicon (Figure
4.2, Step2).
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Figure 4.2
Schematic of Two-Step PCR

Table 4.1
Primers Used for Mutagenesis of Mutacin 1140
Oligonucleotide

Sequence (5ʹ - 3ʹ)

SRWlanA_1
AGAATTCAGGATGCTATCGCTGCTTTTTTTGTG
SRWlanA_2
AGAATTCAGGAAAGTTGCCATATGGTTTTGTG
Trp4Ala_1
GCAAGCCTTTGTACGCCTGGTTG
Trp4Ala_2
ACAAAGGCTTGCACTTTTGAAACG
Trp4insAla_1
GCAAGCCTTTGTACGCCTGGTTG
Trp4insAla_2
CAAAGGCTTGCCCAACTTTTGAAACG
ΔTrp4_1
---AGCCTTTGTACGCCTGGTTG
ΔTrp4_2
CGTACAAAGGCTACTTTTGAAACG
Dha5Ala_1
GCACTTTGTACGCCTGGTTGTGC
Dha5Ala_2
GGCGTACAAAGTGCCCAACTTTTGAA
Alas7insAla_1
GCAACGCCTGGTTGTGCAAGGAC
Alas7insAla_2
ACCAGGCGTTGCACAAAGGCTCC
Arg13Asp_1
GACACAGGTAGTTTCAATAGTTAC
Arg13Asp_2
GAAACTACCTGTGTCTGCACAACCAG
Outside primers are in red type and are homologous to the 5’ and 3’ flanking DNA.
Underlined section represents the engineered EcoRI site. Mutations are either bolded or
dashes. Numbering designates forward (1) and reverse (2) for primers.
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The product was then ligated into a TOPO vector and confirmed by sequencing to
be the proposed mutation. The 1100bp fragment was then cut out of the TOPO vector via
the engineered EcoRI site and re-ligated into the S. mutans suicide vector pVA891.
Sequencing confirmed the proper mutation was present in pVA891. This plasmid
containing the mutated mutA gene was transformed into S. mutans ATCC 55676 through
natural competence similar to previous reports(7, 8) and plated on media supplemented
with 300µg/mL of erythromycin. In order to facilitate the spontaneous recombination
event, the resulting heterodiploids were grown to saturation for several days using the
previous day’s culture as an inoculum. Replica plating of the subcultured heterodiploids
onto media with and without erythromycin allowed visualization of colonies that no
longer harbored the plasmid as they were now erythromycin sensitive. To insure that the
erythromycin sensitivity was due to the loss of the plasmid and not a product of
contamination or human error, colonies were replica plated again on media with and
without the selection antibiotic. For those that were still erythromycin sensitive, DNA
was extracted, subjected to PCR, and sequenced. To confirm that the suspected
erythromycin sensitive colonies contained our mutations, BLAST sequencing was used to
compare the wild-type sequence of mutA to the suspected mutants’ (Figure 4.3). The
mutants generated were: Trp4Ala, Trp4insAla, ΔTrp4, Dha5Ala, Alas7insAla, and
Arg13Asp.
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Trp4Ala
Wild-type
Mutant
Wild-type
Mutant

TTCAAAAGTTGGAGCCTTTGTACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGTTAC
|||||||||
||||||||||||||||||||||||||||||||||||||||||||||||
TTCAAAAGTGCAAGCCTTTGTACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGTTAC
TGTTGCTGA
|||||||||
TGTTGCTGA

Trp4insAla
Wild-type
Mutant
Wild-type
Mutant

TTCAAAAGTTGG---AGCCTTTGTACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGT
||||||||||||
|||||||||||||||||||||||||||||||||||||||||||||
TTCAAAAGTTGGGCAAGCCTTTGTACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGT
TACTGTTGCTGA
|||||||| |||
TACTGTTGTTGA

ΔTrp4
Wild-type
Mutant
Wild-type
Mutant

TTCAAAAGTTGGAGCCTTTGTACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGTTAC
|||||||||
||||||||||||||||||||||||| ||||||||||||||||||||||
TTCAAAAGT---AGCCTTTGTACGCCTGGTTGTGCAAAGACAGGTAGTTTCAATAGTTAC
TGTTGCTGA
|||||||||
TGTTGCTGA

Dha5Ala
Wild-type
Mutant
Wild-type
Mutant

TTCAAAAGTTGGAGCCTTTGTACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGTTAC
||||||||||||
|||||||||||||||||||||||||||||||||||||||||||||
TTCAAAAGTTGGGCACTTTGTACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGTTAC
TGTTGCTGA
|||||||||
TGTTGCTGA

Alas7insAla
Wild-type
Mutant
Wild-type
Mutant

TTCAAAAGTTGGAGCCTTTGT---ACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGT
|||||||||||||||||||||
||||||||||||||||||||||||||||||||||||
TTCAAAAGTTGGAGCCTTTGTGCAACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGT
TACTGTTGCTGA
||||||||||||
TACTGTTGCTGA

Arg13Asp
Wild-type
Mutant
Wild-type
Mutant

TTCAAAAGTTGGAGCCTTTGTACGCCTGGTTGTGCAAGGACAGGTAGTTTCAATAGTTAC
||||||||||||||||||||||||||||||||||||
|||||||||||||||||||||
TTCAAAAGTTGGAGCCTTTGTACGCCTGGTTGTGCAGACACAGGTAGTTTCAATAGTTAC
TGTTGCTGA
|||||||||
TGTTGCTGA

Figure 4.3
BLAST Sequence of Chromosomal DNA Highlighting the Introduced Mutations
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Bioactivity of Mutants
S. mutans ATCC 55676 (wild-type) and the mutants that were at an OD600 of 0.2
were spotted in triplicates on a pre-warmed THyex agar plate (150 X 15mm) and allowed
to dry. This assay was performed in this manner to ensure that each sample had the same
colony size for comparing zones of inhibition. The plate was incubated for 24 hours then
placed in an oven at 50°C for thirty minutes to kill the bacteria before the indicator strain
was overlayed. Heat killing the bacteria prevents any further antimicrobial compound
production and it also ensures that loose bacteria do not get displaced when overlayed
with top agar. Zone diameter was measured in mm across the plate and compared to wildtype (i.e. zone 1 for ATCC compared to zone 1 of Trp4Ala, etc.).
The results showed that Trp4insAla and ΔTrp4 had zones that were not
significantly different than the wild-type (Figures 4.4A and 4.5) as the p-value obtained
was 1. Arg13Asp showed the greatest activity over the wild-type (Figures 4.4B and 4.5)
and was closely followed in activity by Trp4Ala (Figures 4.4A and4.5). Dha5Ala had
slightly higher activity than the wild-type (Figure 4.5) while Alas7insAla had the least
activity of them all (Figures 4.4A and 4.5). Trp4Ala, Dha5Ala, Alas7insAla, and
Arg14Asp all had p-values < 0.05 signifying that their bioactivity was significantly
different from the wild-type.
To obtain purified mutant products minimum media fermentations were
performed as described previously (9). Unfortunately, product was only detected for the
wild-type (data not shown). Also it is possible that the mutants are more capable of
producing the mutant product in a biofilm-like environment, such as what is seen on the
plates, than in a planktonic-like environment, which is more like the condition in the
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fermentation media. Optimization of the fermentation process for these mutants will need
to be developed in order to obtain a product that can be compared to native mutacin 1140.

Figure 4.4
Zone of Inhibition Plate Assay
Both wild-type S. mutans and mutants were grown to an OD600 0.6 then diluted to 0.2.
Two microliters of each sample was then spotted in triplicates, allowed to air dry, then
incubated at 37°C overnight. Bacteria were heat killed by heating in an oven at 55°C for
30 min. After cooling, plates were overlayed with 10mL molten top agar that contained a
standardized cell suspension of M. luteus. Once harden, the plates were inverted and
incubated at 37°C overnight.
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Figure 4.5
Comparison of Zone Diameters for Mutants to Wild-type
Zone size was measured in mm for each sample and compared to wild-type. These
measurements were averaged (n=3) and expressed as percentage of wild-type activity.
Standard deviation was calculated and is represented by the error bars.* indicates mutants
with p-values < 0.05.

Discusion
Natural competence for genetic transformation is the ability of a cell to take up
exogenous free DNA from its surroundings. The DNA that has been taken up can replace
homologous regions of the recipient chromosome thereby causing a permanent change in
the cell’s genetic make-up. This processing pathway depends on the expression of a
unique set of genes whose products are involved in binding, uptake, and integration of
extracellular DNA. For naturally competent streptococci, this process is managed by a
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competence regulation operon that consists of three genes. These genes encode the
competence-stimulating peptide (CSP) precursor (ComC), a histidine kinase (ComD),
and a cognate response regulator (ComE) (10, 11). Once the secreted CSP has reached a
certain concentration, it signals the membrane-bound CSP receptor, ComD to
phosphorylate the cognate response regulator, ComE which presumably acts at promoter
sites for genes whose expression levels are upregulated during the development
ofcompetence(11, 12).Perry and Kuramitsu were the first to demonstrate natural
transformation in S. mutans when they showed that three strains of S. mutans could
acquire streptomycin resistance by natural genetic transfer(8). They later found that a
number of cariogenic properties and production of bacteriocins could also be acquired by
the same method(13). In this study, we utilized this knowledge to transform a suicide
vector (pVA891) harboring a mutated mutA gene into S. mutans JH1140.
Various mutations have been made to ring B for nisin (14-19), thus our studies
focused on ringAand the hinge region. Rarely have there been mutations that result in
increased bioactivity. More often the results of mutation to lantibiotics lead to mutants
with no bioactivity, reduced (slightly or drastically), or similar bioactivity(17, 19-22).
The results from this study revealed some mutants with increased or similar bioactivity
lending to some interesting insight into the structural integrity of mutacin 1140.
The Trp4insAla mutant yielded a product that had bactericidal activity similar to
wild-type mutacin 1140. The same result was seen for the deletion of tryptophan at
position 4 suggesting that shortening or lengthening of ring A has no ill effect on
bioactivity and more importantly it demonstrates the overall flexibility of ring A. It can
be speculated that removal or addition of an amino acid to this ring has no deleterious
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effects on the biosynthesis machinery as an active product was obviously produced and
exported. The mutation replacing tryptophan at position 4 with alanine results in a 26%
increase in bioactivity when compared to the wild-type. Since both amino acids are
uncharged and hydrophobic, it can be concluded that the difference in bioactivity is due
to the size difference between the two amino acids. When considering the biosynthesis of
lantibiotics, the increased activity seen can be due to a more efficient processing and
exporting of the mutated peptide. It is well known that lantibiotic production is regulated
by quorum sensing(23). This has been demonstrated for nisin, which acts as its own
autoinducer for nisin production (24). The Trp4Ala mutant could possibly be a better
autoinducer of mutacin 1140 production and thus the reason for the increased bactericidal
activity seen.To determine if this is the reason for the increase in bioactivity, a
fermentation would need to be performed to compare mutacin 1140 production between
the wild-type and mutants. This mutation again demonstrates the flexibility and of ring A.
Replacement of Dha, a residue that starts out as a serine and is later dehydrated
during post-translation modification, with alanine also results in a slight increase (8%) in
bioactivity. When this same mutation was made in nisin, the product showed similar
bioactivity when compared to wild-type nisin(14). This mutation is very useful as it limits
the number of dehydrated residues in mutacin 1140. With only one dehydrated residue
remaining, the same methods used to fluorescently label gallidermin (see Chapter III for
review) can be used to label mutacin 1140. Utilizing this mutant may make it possible to
acquire the first ever images of mutacin 1140 in vivo.
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Adding an alanine after SAla at position 7 resulted in an approximately 40%
reduction of bioactivity. Apparently, having separation between rings A and B alters the
bioactivity of the resultant peptide. Since it has been determined thatSAla7freely rotates
360º allowing ring A to spin freely with respect to ring B(4), it can be concluded that the
aforementioned mutation changes the orientation of the rings during lipid II binding. This
notion is further supported given that the side chain of sAla is part of the nisin-lipid II
complex pyrophosphate cage moiety (25). Another possibility is that the mutated peptide
is not well tolerated by the biosynthesis machinery and is not processed and exported out
of the cell as efficiently as the other mutants or wild-type.
The most interesting result was obtained for the Arg13Asp mutant. This mutation
resulted in a 27% increase in bioactivity when compared to the wild-type. Here there was
a replacement of a positively charged hydrophobic residue for a negatively charged
hydrophilic residue in the hinge region. The conventional thought is that negative charges
for lantibiotics would reduce bioactivity. Positive charges are thought to aid in the
interaction of the antibiotic with the negatively charged lipids. However, this assumption
has been disproven as a reduction in overall charge was not only tolerated but resulted in
a mutant with increased activity. This mutation also removed a trypsin cleavable site
from the compound making it more stable in the digestive tract. Also, a carboxyl group
was incorporated into the peptide which would be amendable to the same labeling
procedure as is done with the C-terminus of nisin (26).
From this study it can be concluded that ring A and the hinge region are
amendable to modifications. Interestingly, Trp4 and Dha5 have been found to be nonessential for bactericidal activity of mutacin 1140. Mutations of Dha5 have been
130

previously performed, and those results confirm the conclusion of its non-essential role in
bactericidal activity (14, 27). However, this is the first study in which the role of Trp4 has
been explored. It is interesting to discover that not only is it non-essential, but that
replacing it can lead to a modified peptide with increased activity. Likewise, this study
revealed that either increasing the length between rings A and B or reducing their
flexibility leads to a drastic decrease in bioactivity. This finding has never been reported
for any type A (I) lantibiotic. Through this study, mutants were generated that have
increased the overall knowledge of mutacin 1140 structure-activity relationship and has
opened the door to explore mutacin 1140 in vivo. Also, the data from this study supports
the proposed hypothesis as there was an alteration in bioactivity of the generated mutants.

131

Bibliography
1.

Hasper, H. E., Kramer, N. E., Smith, J. L., Hillman, J. D., Zachariah, C., Kuipers,
O. P., de Kruijff, B., and Breukink, E. (2006) An alternative bactericidal
mechanism of action for lantibiotic peptides that target lipid II, Science 313,
1636-1637.

2.

Smith, L., Hasper, H., Breukink, E., Novak, J., Cerkasov, J., Hillman, J. D.,
Wilson-Stanford, S., and Orugunty, R. S. (2008) Elucidation of the antimicrobial
mechanism of mutacin 1140, Biochemistry 47, 3308-3314.

3.

Ghobrial, O. G., Derendorf, H., and Hillman, J. D. (2009) Pharmacodynamic
activity of the lantibiotic MU1140, International Journal of Antimicrobial Agents
33, 70-74.

4.

Smith, L., Zachariah, C., Thirumoorthy, R., Rocca, J., Novák, J., Hillman, J. D.,
and Edison, A. S. (2003) Structure and dynamics of the lantibiotic mutacin 1140,
Biochemistry 42, 10372-10384.

5.

Hillman, J. D., Johnson, K. P., and Yaphe, B. I. (1983) Characterization of a
Streptococcus mutans bacteriocin with novel properties, Journal of Dental
Research 62, 241-241.

6.

Hillman, J. D., Johnson, K. P., and Yaphe, B. I. (1984) Isolation of a
Streptococcus mutans strain producing a novel bacteriocin, Infection and
Immunity 44, 141-144.

7.

Hillman, J. D., Brooks, T. A., Michalek, S. M., Harmon, C. C., Snoep, J. L., and
van der Weijden, C. C. (2000) Construction and characterization of an effector
strain of Streptococcus mutans for replacement therapy of dental caries, Infection
and Immunity 68, 543-549.

8.

Perry, D., and Kuramitsu, H. K. (1981) Genetic transformation of Streptococcus
mutans, Infection and Immunity 32, 1295-1297.

9.

Dahal, N., Chaney, N., Ellis, D., Lu, S.-E., and Smith, L. (2010) Optimization of
the production of the lantibiotic mutacin 1140 in minimal media, Process
Biochemistry 45, 1187-1191

10.

Cheng, Q., Campbell, E. A., Naughton, A. M., Johnson, S., and Masure, H. R.
(1997) The com locus controls genetic transformation in Streptococcus
pneumoniae, Molecular Microbiology 23, 683-692.

132

11.

Håvarstein, L. S., Gaustad, P., Nes, I. F., and Morrison, D. A. (1996)
Identification of the streptococcal competence-pheromone receptor, Molecular
Microbiolog y21, 863-869.

12.

Stock, J. B., Ninfa, A. J., and Stock, A. M. (1989) Protein phosphorylation and
regulation of adaptive responses in bacteria., Microbiology Review 53, 450-490.

13.

Perry, D., Wondrack, L. M., and Kuramitsu, H. K. (1983) Genetic transformation
of putative cariogenic properties in Streptococcus mutans, Infection and Immunity
41, 722-727.

14.

Chan, W. C., Dodd, H. M., Horn, N., Maclean, K., Lian, L. Y., Bycroft, B. W.,
Gasson, M. J., and Roberts, G. C. (1996) Structure-activity relationships in the
peptide antibiotic nisin: role of dehydroalanine 5, Applied and Environmental
Microbiology 62, 2966-2969.

15.

Dodd, H. M., Horn, N., Chan, W. C., Giffard, C. J., Bycroft, B. W., Roberts, G.
C., and Gasson, M. J. (1996) Molecular analysis of the regulation of nisin
immunity, Microbiology (Reading, England)142 ( Pt 9), 2385-2392.

16.

Kuipers, O. P., Bierbaum, G., Ottenwälder, B., Dodd, H. M., Horn, N., Metzger,
J., Kupke, T., Gnau, V., Bongers, R., van den Bogaard, P., Kosters, H., Rollema,
H. S., de Vos, W. M., Siezen, R. J., Jung, G., Götz, F., Sahl, H. G., and Gasson,
M. J. (1996) Protein engineering of lantibiotics, Antonie Van Leeuwenhoek 69,
161-169.

17.

Rink, R., Wierenga, J., Kuipers, A., Kluskens, L. D., Driessen, A. J. M., Kuipers,
O. P., and Moll, G. N. (2007) Dissection and modulation of the four distinct
activities of nisin by mutagenesis of rings A and B and by C-terminal truncation,
Applied and Environmental Microbiology 73, 5809-5816.

18.

van Kraaij, C., Breukink, E., Rollema, H. S., Bongers, R. S., Kosters, H. A., de
Kruijff, B., and Kuipers, O. P. (2000) Engineering a disulfide bond and free thiols
in the lantibiotic nisin Z, European Journal of Biochemistry 267, 901-909.

19.

Wiedemann, I., Breukink, E., van Kraaij, C., Kuipers, O. P., Bierbaum, G., de
Kruijff, B., and Sahl, H. A. (2001) Specific binding of nisin to the peptidoglycan
precursor lipid II combines pore formation and inhibition of cell wall biosynthesis
for potent antibiotic activity, Journal of Biological Chemistry 276, 1772-1779.

20.

Bierbaum, G., Szekat, C., Josten, M., Heidrich, C., Kempter, C., Jung, G., and
Sahl, H. G. (1996) Engineering of a novel thioether bridge and role of modified
residues in the lantibiotic pep5, Applied and Environmental Microbiology 62,
385-392.
133

21.

Bonelli, R. R., Schneider, T., Sahl, H. G., and Wiedemann, I. (2006) Insights into
in vivo activities of lantibiotics from gallidermin and epidermin mode-of-action
studies, Antimicrobial Agents and Chemotherapy 50, 1449-1457.

22.

Ottenwälder, B., Kupke, T., Brecht, S., Gnau, V., Metzger, J., Jung, G., and Götz,
F. (1995) Isolation and characterization of genetically engineered gallidermin and
epidermin analogs, Applied and Environmental Microbiology 61, 3894-3903.

23.

Dufour, A., Hindre, T., Haras, D., and Le Pennec, J. P. (2007) The biology of
lantibiotics from the lacticin 481 group is coming of age, FEMS Microbiology
Reviews 31, 134-167.

24.

Entian, K. D., and de Vos, W. M. (1996) Genetics of subtilin and nisin
biosyntheses: biosynthesis of lantibiotics, Antonie Van Leeuwenhoek 69, 109-117.

25.

Hsu, S. T. D., Breukink, E., Tischenko, E., Lutters, M. A. G., de Kruijff, B.,
Kaptein, R., Bonvin, A., and van Nuland, N. A. J. (2004) The nisin-lipid II
complex reveals a pyrophosphate cage that provides a blueprint for novel
antibiotics, Nature Structural and Molecular Biology 11, 963-967.

26.

Wilson-Stanford, S., Kalli, A., Hakansson, K., Kastrantas, J., Orugunty, R. S., and
Smith, L. (2009) Oxidation of lanthionines renders the lantibiotic nisin inactive,
Applied and Environmental Microbiology 75, 1381-1387.

27.

Liu, W., and Hansen, J. N. (1992) Enhancement of the chemical and antimicrobial
properties of subtilin by site-directed mutagenesis, The Journal Of Biological
Chemistry 267, 25078-25085.

134

CHAPTER V
CONCLUSIONS AND FUTURE DIRECTIONS

Bacteriocins are proteinaceous molecules produced by bacteria to inhibit the
growth of competing closely related bacterial strains. The work in this dissertation is
focused on the bacteriocins nisin, gallidermin, and mutacin 1140. They are all type A (I)
lantibiotics produced by Lactococcus lactis, Staphylococcus gallinarium, and
Streptococcus mutans JH1140 respectively. Type A lantibiotics have a molecular mass
greater than 2100 Da, a net positive charge ranging from 2-7, and rigid ring
conformations that are separated by areas of flexibility.
The findings from this study include: 1) The development of an efficient chemical
modification procedure for generating oxidized variants of lantibiotics and determination
of the effect oxidation has on bactericidal activity, 2) The development of an efficient
method of utilizing the dehydro amino acids found in lantibiotics to label and visualize in
vivo lantibiotics that cannot be fluorescently labeled by conventional means. This also led
to the generatation of bioactive thiol containing variants of lantibiotics, and 3) The
identification of both essential and non-essential residues in mutacin 1140.
Using hydrogen peroxide under mildly acidic conditions proved to be a simple
and efficient method for generating oxidized variants of both nisin A and gallidermin.
The FT-ICR MS data for the oxidized variant of nisin A showed that approximately 48%
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of oxidized nisin A contained an addition of seven oxygens, 39% had an addition of
eight, and approximately 14% had an addition of nine. These data were predictable
because they correlate well with the structure of nisin A which has five lanthionine rings,
two methionines, and two histidines, all of which are susceptible to oxidation with
hydrogen peroxide.
Bactericidal assays, TEM, and a lipid II affinity assay were developed to
characterize the bioactive properties of oxidized nisin A. Both qualitative and quantitative
bioassays were performed to determine the bioactivity of the oxidized variants. Oxidation
of both nisin and gallidermin led to a complete loss of bactericidal activity. To investigate
whether this loss of bioactivity was due to impaired lateral assembly or reduced affinity
of lipid II, TEM and a TLC assay for lipid II binding were performed.
TEM showed that the oxidized variant was still capable of forming large circular
complexes on the carbon-coated grids, suggesting that the ability for lateral assembly of
the oxidized variants was not affected. The results of the TLC lipid II binding assay
showed that oxidized nisin A was not able to bind to lipid II and inhibit its migration
even at a 12:1 ratio. This suggested that the loss of bioactivity was due to the loss of
affinity for lipid II. Confocal laser scanning microscopy was then used to determine
whether the loss of lipid II binding could also be observed in vivo. The results from this
experiment confirmed the findings from the TLC assay.
In this aim, an oxidized variant of nisin was generated that is biologically inactive
but is still capable of lateral assembly. The findings from this investigation reveal new
areas of study of the effects of lantibiotic oxidation, including mechanisms for potential
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resistance pathways. Also this research shows that studies to determine the effect
oxidation has on the pharmacokinetics and pharmacodynamics of lantibiotics are needed.
The second aim of this study revealed an efficient method of utilizing the dehydro
amino acids found in lantibiotics to label and visualize in vivo, lantibiotics that cannot be
fluorescently labeled by conventional means. A simple method to generate various thiol
containing chemical derivatives of gallidermin was developed. In this method, the
lantibiotic was incubated in a buffered solution that contained the thiol compound of
choice. Three thiol containing compounds were used (β-mercaptoethanol, ethanethiol,
and thiolactic acid) because of their varying properties. MALDI data confirmed the single
and double addition of the compounds to the parent antibiotic. A quantitative bioassay
was performed to determine the effect of adding these thiol compounds, and results
showed that all of them were bioactive in the nanomolar concentration range.
A TLC lipid II binding assay was used to determine if lipid II binding was
affected by the addition of the thiol compounds. Some samples were not tested due to the
small quantity obtained. However, for the chemical derivatives that were tested (βmercaptoethanol and thiolactic acid) it was shown that affinity for lipid II binding was
somewhat reduced as a higher ratio was needed to inhibit migration of lipid II.
Using the same method used to add the thiol compounds to gallidermin, SAMSA
(a thiol containing fluorescein) was used to fluorescently label gallidermin. This was a
major advancement for lantibiotics that do not have a free C-terminus available for
fluorescent labeling as it provided a way to view, in vivo, lantibiotics that cannot be
labeled in the conventional way. Results showed that gallidermin has the same lipid II
clustering pattern that was seen for nisin. Taking advantage of the reactivity of the
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dehydro amino acids found in lantibiotics opens doors to a new era of research where
these residues can be used to make modifications that could possibly increase bioactivity,
solubility, or stability of the targeted lantibiotic.
The last aim of this study investigated the importance of several key residues in
mutacin 1140. It has been speculated that the flexibility of the lanthionine rings and hinge
region are key in proper orientation of mutacin 1140 during lipid II binding. Some
important residues thought to be involved in this flexibility are Trp4, Dha5, and SAla7.
Another interesting residue present in the mutacin 1140 propeptide is a protease
susceptible arginine at position 13. Utilizing a two-step PCR method and standard
molecular techniques several mutants were constructed and transformed through natural
competence into S. mutans ATCC 55676.
Genomic DNA from suspected mutants was extracted, amplified by PCR, and
sequenced. Sequences were compared to the wild-type mutA gene to insure that the
proper mutation was achieved. Fermentation of the mutants was performed in both
complex media and minimal media. The results showed that for the mutants, no mutated
mutacin was produced in the minimum media. No mutacin was produced for any of the
samples when fermentation was performed in complex media. For this reason, further
evaluation of the mutants was performed using a plate assay to determine the differences
between the mutants and wild-type S. mutans.
A zone of inhibition plate assay was used to determine if the mutations had an
effect on bactericidal activity. There was no significant difference between zone
diameters for Trp4insAla and ΔTrp4 and the wild-type. Interestingly, several mutants
showed an increase in bioactivity when compared to the wild-type. These were Trp4Ala,
138

Dha5Ala, and Arg13Asp. This was a very unusual finding as most mutational studies
result in mutants with either a complete loss or drastic reduction in bioactivity. The only
mutation that showed a decrease in bioactivity was Alas7insAla. These results
demonstrate that ring A has some promiscuity in amino acid residues 4 and 5. It also
demonstrates that the size of the ring can vary without causing any deleterious effects.
However, the reduction in activity seen for Alas7insAla suggests that the distance
between rings A and B is essential to bioactivity.
There are several ways to proceed with studies of lantibiotics based on the
knowledge gained herein. For the thiol chemistry, optimization of reaction buffer, time,
and temperature need to be performed to attempt to reduce or eliminate the amount of
double labeled and unlabeled material. Also, long term storage conditions must be
examined as the current conditions lead to denaturation of the generated chemical
derivatives. Scaling the process up would produce more material to be available to
perform subsequent assays. Additional assays to perform are TLC for lipid II binding and
TEM for lateral assembly.
For the mutagenesis analysis of mutacin 1140, more mutants need to be
generated. Constructs for mutations that span the entire peptide have already been made,
and only these need to be transformed into S. mutans or ligated into the suicide vector
pVA891 then transformed. Once these mutants have been confirmed, optimization of the
fermentation process must be performed to produce mutant mutacin that can be compared
to native mutacin 1140. Once this has been done, the mutant product can be compared to
wild-type mutacin 1140 in the areas of lateral assembly, quantitative bioactivity, and lipid
II binding.
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